

## WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, August 01, 2006

<b>Hide?</b>	<b>Set Name</b>	<b>Query</b>	<b>Hit Count</b>
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L6	(L5 and pMUC10)	5
<input type="checkbox"/>	L5	(L2 and monoclonal)	29
<input type="checkbox"/>	L4	(L2 and tanden repeat)	0
<input type="checkbox"/>	L3	L2 and "SM-3 near antibody"	0
<input type="checkbox"/>	L2	(L1 and SM-3)	30
<input type="checkbox"/>	L1	human and "polymorphic epithelial mucin"	341

END OF SEARCH HISTORY

## Welcome to DialogClassic Web(tm)

Dialog level 05.12.03D  
 Last logoff: 01aug06 10:58:14  
 Logon file001 01aug06 13:44:09  
 \* \* \*

File 1:ERIC 1966-2006/June  
 (c) format only 2006 Dialog

Set	Items	Description
---	-----	-----

Cost is in DialUnits  
 ?

B 155, 159, 10, 203, 35, 5, 467, 73, 434, 34  
 01aug06 13:44:38 User290558 Session D63.1  
 \$0.40 0.113 DialUnits File1  
 \$0.40 Estimated cost File1  
 \$0.13 INTERNET  
 \$0.53 Estimated cost this search  
 \$0.53 Estimated total session cost 0.113 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1950-2006/Jul 31

(c) format only 2006 Dialog

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog

**\*File 159: Cancerlit is no longer updating.**

Please see HELP NEWS159.

File 10:AGRICOLA 70-2006/May

(c) format only 2006 Dialog

File 203:AGRIS 1974-2006/Mar

Dist by NAL, Intl Copr. All rights reserved

File 35:Dissertation Abs Online 1861-2006/Jun

(c) 2006 ProQuest Info&Learning

File 5:Biosis Previews(R) 1969-2006/Jul W4

(c) 2006 The Thomson Corporation

File 467:ExtraMED(tm) 2000/Dec

(c) 2001 Informania Ltd.

**\*File 467: F467 will close on February 1, 2006.**

7.

File 73:EMBASE 1974-2006/Aug 01

(c) 2006 Elsevier Science B.V.

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec

(c) 2006 The Thomson Corp

File 34:SciSearch(R) Cited Ref Sci 1990-2006/Jul W4

(c) 2006 The Thomson Corp

Set	Items	Description
---	-----	-----

?

S (POLYMORPHIC (N) EPITHELIAL (N) MUCIN) AND CLONE

170176 POLYMORPHIC

729373 EPITHELIAL

54146 MUCIN

1118 POLYMORPHIC (N) EPITHELIAL (N) MUCIN

305297 CLONE

S1 27 (POLYMORPHIC (N) EPITHELIAL (N) MUCIN) AND CLONE

?

S (EPITHELIAL (W) MUCIN) AND CLONE  
       729373 EPITHELIAL  
       54146 MUCIN  
       2156 EPITHELIAL(W)MUCIN  
       305297 CLONE  
   S2      43 (EPITHELIAL (W) MUCIN) AND CLONE  
 ?

Set	Items	Description
S1	27	(POLYMORPHIC (N) EPITHELIAL (N) MUCIN) AND CLONE
S2	43	(EPITHELIAL (W) MUCIN) AND CLONE

?

S S1 AND SM-3  
       27 S1  
       84 SM-3  
   S3      0 S1 AND SM-3  
 ?

S S2 AND SM-3  
       43 S2  
       84 SM-3  
   S4      0 S2 AND SM-3  
 ?

Set	Items	Description
S1	27	(POLYMORPHIC (N) EPITHELIAL (N) MUCIN) AND CLONE
S2	43	(EPITHELIAL (W) MUCIN) AND CLONE
S3	0	S1 AND SM-3
S4	0	S2 AND SM-3

?

S (S1 AND (SM (W) 3))  
 Processing  
 Processed 10 of 10 files ...  
 Completed processing all files  
       27 S1  
       63392 SM  
       12222278 3  
       732 SM(W)3  
   S5      1 (S1 AND (SM (W) 3))  
 ?

Set	Items	Description
S1	27	(POLYMORPHIC (N) EPITHELIAL (N) MUCIN) AND CLONE
S2	43	(EPITHELIAL (W) MUCIN) AND CLONE
S3	0	S1 AND SM-3
S4	0	S2 AND SM-3
S5	1	(S1 AND (SM (W) 3))

?

S S2 AND (SM (W) 3))  
 >>>Unmatched parentheses  
 ?

S S2 AND (SM (W) 3)  
 Processing

```

      43  S2
    63392 SM
  12222278 3
      732 SM(W)3
S6         1 S2 AND (SM (W) 3)

```

?

Set	Items	Description
S1	27	(POLYMORPHIC (N) EPITHELIAL (N) MUCIN) AND CLONE
S2	43	(EPITHELIAL (W) MUCIN) AND CLONE
S3	0	S1 AND SM-3
S4	0	S2 AND SM-3
S5	1	(S1 AND (SM (W) 3))
S6	1	S2 AND (SM (W) 3)
?		

TYPE S5/FULL/1

5/9/1 (Item 1 from file: 155)  
 DIALOG(R)File 155:MEDLINE(R)  
 (c) format only 2006 Dialog. All rts. reserv.

09146831 PMID: 1370949

**Characterization of epithelial phenotypes in mortal and immortal human breast cells.**

Paine T M; Soule H D; Pauley R J; Dawson P J  
 Michigan Cancer Foundation, Detroit 48201.

International journal of cancer. Journal international du cancer (UNITED STATES) Feb 1 1992, 50 (3) p463-73, ISSN 0020-7136--Print  
 Journal Code: 0042124

Contract/Grant No.: CA22453; CA; NCI; RR05529; RR; NCRR

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

We have previously described the mortal human breast epithelial culture MCF-10M, that was derived from fibrocystic breast tissue, was cultivated in medium with low calcium content for over 2 years, and spontaneously gave rise to the immortal MCF-10 cell line. The emergence of immortalized cells, characterized by growth in conventional calcium levels, from mortal cells has proven to be a reproducible event. Here we report the establishment of a second immortal line from MCF-10M, designated MCF-10-2, and establishment of the MCF-12 immortal line after long-term cultivation of MCF-12M mortal cells from reduction mammoplasty tissue. DNA fingerprinting demonstrated the independent, human origin and lineage of the MCF-10-2 and MCF-12 cell lines. Both lines require cortisol and EGF for maximal growth. The expression in these cultures of in vivo breast epithelial phenotypes was analyzed using 2-dimensional gel Western blots and immunoperoxidase staining with antibodies to cytokeratins and polymorphic epithelial mucin. MCF-10M and MCF-12M retain the cytokeratin profile of the luminal cell (7, 8, 18, 19), and also express cytokeratin 14, found predominantly in basal cells. The immortal lines express a similar profile, except that cytokeratin 19, a component of the fully differentiated luminal cell, is not expressed in the more uniform population seen in MCF-10 and MCF-12, but is retained in the morphologically mixed, less-selected population of MCF-10-2. Epitopes on the polymorphic epithelial mucin, recognized by antibodies HMFG 1, HMFG 2 and SM-3, were detected in the mortal cultures

and in the immortal lines, indicating the occurrence of both normal and abnormal mucin processing. MCF-10, MCF-10-2 and MCF-12 cells do not form tumors in nude mice, but appear to organize as duct-like structures before regressing in the 5th week post injection.

Descriptors: \*Breast--cytology--CY; Animals; Antibodies, Monoclonal; Blotting, Western; Breast--immunology--IM; Cell Division; Cell Line; Cell Survival; Clone Cells; DNA Fingerprinting; Electrophoresis, Gel, Two-Dimensional; Epithelial Cells; Epithelium--immunology--IM; Humans; Immunoenzyme Techniques; In Vitro; Keratin--chemistry--CH; Mice; Mice, Nude ; Polymorphism, Restriction Fragment Length; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Time Factors

CAS Registry No.: 0 (Antibodies, Monoclonal); 68238-35-7 (Keratin)

Record Date Created: 19920306

Record Date Completed: 19920306

?

Set	Items	Description
S1	27	(POLYMORPHIC (N) EPITHELIAL (N) MUCIN) AND CLONE
S2	43	(EPITHELIAL (W) MUCIN) AND CLONE
S3	0	S1 AND SM-3
S4	0	S2 AND SM-3
S5	1	(S1 AND (SM (W) 3))
S6	1	S2 AND (SM (W) 3)

?

TYPE S6/FULL/1

6/9/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

09146831 PMID: 1370949

**Characterization of epithelial phenotypes in mortal and immortal human breast cells.**

Paine T M; Soule H D; Pauley R J; Dawson P J

Michigan Cancer Foundation, Detroit 48201.

International journal of cancer. Journal international du cancer (UNITED STATES) Feb 1 1992, 50 (3) p463-73, ISSN 0020-7136--Print

Journal Code: 0042124

Contract/Grant No.: CA22453; CA; NCI; RR05529; RR; NCRR

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

We have previously described the mortal human breast epithelial culture MCF-10M, that was derived from fibrocystic breast tissue, was cultivated in medium with low calcium content for over 2 years, and spontaneously gave rise to the immortal MCF-10 cell line. The emergence of immortalized cells, characterized by growth in conventional calcium levels, from mortal cells has proven to be a reproducible event. Here we report the establishment of a second immortal line from MCF-10M, designated MCF-10-2, and establishment of the MCF-12 immortal line after long-term cultivation of MCF-12M mortal cells from reduction mammaplasty tissue. DNA fingerprinting demonstrated the independent, human origin and lineage of the MCF-10-2 and MCF-12 cell lines. Both lines require cortisol and EGF for maximal growth. The expression in these cultures of in vivo breast epithelial phenotypes was analyzed using 2-dimensional gel Western blots and immunoperoxidase

staining with antibodies to cytokeratins and polymorphic epithelial mucin. MCF-10M and MCF-12M retain the cytokeratin profile of the luminal cell (7, 8, 18, 19), and also express cytokeratin 14, found predominantly in basal cells. The immortal lines express a similar profile, except that cytokeratin 19, a component of the fully differentiated luminal cell, is not expressed in the more uniform population seen in MCF-10 and MCF-12, but is retained in the morphologically mixed, less-selected population of MCF-10-2. Epitopes on the polymorphic epithelial mucin, recognized by antibodies HMFG 1, HMFG 2 and SM-3, were detected in the mortal cultures and in the immortal lines, indicating the occurrence of both normal and abnormal mucin processing. MCF-10, MCF-10-2 and MCF-12 cells do not form tumors in nude mice, but appear to organize as duct-like structures before regressing in the 5th week post injection.

Descriptors: \*Breast--cytology--CY; Animals; Antibodies, Monoclonal; Blotting, Western; Breast--immunology--IM; Cell Division; Cell Line; Cell Survival; Clone Cells; DNA Fingerprinting; Electrophoresis, Gel, Two-Dimensional; Epithelial Cells; Epithelium--immunology--IM; Humans; Immunoenzyme Techniques; In Vitro; Keratin--chemistry--CH; Mice; Mice, Nude; Polymorphism, Restriction Fragment Length; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Time Factors

CAS Registry No.: 0 (Antibodies, Monoclonal); 68238-35-7 (Keratin)

Record Date Created: 19920306

Record Date Completed: 19920306

?

S ((SM (W) 3) AND (MONOCLONAL OR ANTIBODY))

>>>Unmatched parentheses

?

S (SM (W) 3) AND MONOCLONAL OR ANTIBODY

Processing

Processed 10 of 10 files ...

Completed processing all files

63392	SM
12222278	3
732	SM(W)3
849081	MONOCLONAL
1764982	ANTIBODY
S7 1765000	((SM (W) 3) AND MONOCLONAL OR ANTIBODY)

?

S ((SM (W) 3) AND MONOCLONAL OR ANTIBODY)

Processing

63392	SM
12222278	3
732	SM(W)3
849081	MONOCLONAL
1764982	ANTIBODY
S8 1765000	((SM (W) 3) AND MONOCLONAL OR ANTIBODY)

?

S ((SM (W) 3) AND ANTIBODY)

63392	SM
12222278	3
732	SM(W)3
1764982	ANTIBODY
S9 88	((SM (W) 3) AND ANTIBODY)

?

S S9 AND MUCIN

```

      88  S9
    54146 MUCIN
S10      50  S9 AND MUCIN
?
```

```

S (S10 AND GENE OR CLONE)
      50  S10
    4322169 GENE
    305297 CLONE
S11 305313 (S10 AND GENE OR CLONE)
?
```

Set	Items	Description
S1	27	(POLYMORPHIC (N) EPITHELIAL (N) MUCIN) AND CLONE
S2	43	(EPITHELIAL (W) MUCIN) AND CLONE
S3	0	S1 AND SM-3
S4	0	S2 AND SM-3
S5	1	(S1 AND (SM (W) 3))
S6	1	S2 AND (SM (W) 3)
S7	1765000	(SM (W) 3) AND MONOCLONAL OR ANTIBODY
S8	1765000	((SM (W) 3) AND MONOCLONAL OR ANTIBODY)
S9	88	((SM (W) 3) AND ANTIBODY)
S10	50	S9 AND MUCIN
S11	305313	(S10 AND GENE OR CLONE)

?

```

S (S10 AND CLONE)
      50  S10
    305297 CLONE
S12      4  (S10 AND CLONE)
?
```

Set	Items	Description
S1	27	(POLYMORPHIC (N) EPITHELIAL (N) MUCIN) AND CLONE
S2	43	(EPITHELIAL (W) MUCIN) AND CLONE
S3	0	S1 AND SM-3
S4	0	S2 AND SM-3
S5	1	(S1 AND (SM (W) 3))
S6	1	S2 AND (SM (W) 3)
S7	1765000	(SM (W) 3) AND MONOCLONAL OR ANTIBODY
S8	1765000	((SM (W) 3) AND MONOCLONAL OR ANTIBODY)
S9	88	((SM (W) 3) AND ANTIBODY)
S10	50	S9 AND MUCIN
S11	305313	(S10 AND GENE OR CLONE)
S12	4	(S10 AND CLONE)

?

```

S (S10 AND DNA)
      50  S10
    3792863 DNA
S13      7  (S10 AND DNA)
?
```

Set	Items	Description
S1	27	(POLYMORPHIC (N) EPITHELIAL (N) MUCIN) AND CLONE
S2	43	(EPITHELIAL (W) MUCIN) AND CLONE
S3	0	S1 AND SM-3

```

S4          0    S2 AND SM-3
S5          1    (S1 AND (SM (W) 3))
S6          1    S2 AND (SM (W) 3)
S7    1765000    (SM (W) 3) AND MONOCLONAL OR ANTIBODY
S8    1765000    ((SM (W) 3) AND MONOCLONAL OR ANTIBODY)
S9          88    ((SM (W) 3) AND ANTIBODY)
S10         50    S9 AND MUCIN
S11    305313    (S10 AND GENE OR CLONE)
S12         4    (S10 AND CLONE)
S13         7    (S10 AND DNA)
?
```

TYPE S10/MEDIUM,K/1-50

10/K/1 (Item 1 from file: 155)  
 DIALOG(R)File 155:MEDLINE(R)  
 (c) format only 2006 Dialog. All rts. reserv.

12511522 PMID: 10455130

**Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes.**

Beum P V; Singh J; Burdick M; Hollingsworth M A; Cheng P W  
 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA.

Journal of biological chemistry (UNITED STATES) Aug 27 1999, 274 (35)  
 p24641-8, ISSN 0021-9258--Print Journal Code: 2985121R  
 Contract/Grant No.: HL48242; HL; NHLBI; P30 CA36727; CA; NCI; R01 CA69234  
 ; CA; NCI

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... stable transfection of a human pancreatic adenocarcinoma cell line, Panc1-MUC1, with the cDNA for mucin core 2 GlcNAc-transferase (C2GnT), which creates the core 2 beta-1,6 branch in mucin -type glycans. These cells lack endogenous C2GnT activity but express a recombinant human MUC1 cDNA...

... clones expressing different levels of C2GnT were characterized using monoclonal antibodies CC49, CSLEX-1, and SM - 3 , which recognize tumor-associated epitopes. Increased C2GnT expression led to greatly diminished expression of the...

... transfectants could not bind to selectins. Increased C2GnT expression also led to masking of the SM - 3 peptide epitope, which persisted after the removal of sialic acid, further suggesting greater complexity of...

...Chemical Name: 3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; Antibodies, Monoclonal; Antibodies, Neoplasm; B72.3 antibody ; CA-15-3 Antigen; Epitopes; Mucins; Oligosaccharides; Peptides; Polysaccharides; SM3-MUC1 peptide; N-Acetylneuraminic Acid...

10/K/2 (Item 2 from file: 155)  
 DIALOG(R)File 155:MEDLINE(R)  
 (c) format only 2006 Dialog. All rts. reserv.

12055862 PMID: 9923971



**A short synthetic peptide (DTRPAP) induces anti-mucin (MUC-1) antibody, which is reactive with human ovarian and breast cancer cells.**

Avichezer D; Taylor-Papadimitriou J; Arnon R  
Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel.

Cancer biochemistry biophysics (ENGLAND) Jun 1998, 16 (1-2) p113-28, ISSN 0305-7232--Print Journal Code: 7506524

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

**A short synthetic peptide (DTRPAP) induces anti- mucin (MUC-1) antibody , which is reactive with human ovarian and breast cancer cells.**

The present study describes the production of a synthetic hexapeptide (DTRPAP)-based anti- mucin (MUC-1) antibody , similar to those produced using either the intact mucin antigen or tumor extracts. This antibody was generated by immunization of rabbits with the synthetic peptide conjugated to bovine serum albumin...

...a carrier. Using both the ELISA and FACS analysis methods, we have shown that the antibody is reactive with human ovarian and breast cancer cells, but not with normal epithelial breast cells. This antibody is different from the previously reported anti- mucin HMFG-1, HMFG-2 and SM - 3 monoclonal antibodies, since competitive experiments with the free synthetic peptide revealed only a 30% inhibition...

... ovarian (OVCAR-3) cancer cells, as compared to 78% inhibition of the anti-synthetic peptide antibody . The peptide was non-inhibitory for HMFG-2, and induced a significant and reproducible stimulation of the SM - 3 binding activity to the tumor cells.

; Animals; Antibodies--metabolism--ME; Antibody Specificity; Cytotoxicity, Immunologic; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Mice; Mice, Nude; Neoplasm Transplantation...

10/K/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

09554550 PMID: 7679052

**Multiple forms of intracellular and secreted mucins in a pancreatic cancer cell line.**

Ho J J; Bi N; Siddiki B; Chung Y S; Yuan M; Kim Y S  
Gastrointestinal Research Laboratory, Veterans Affairs Medical Center, San Francisco, California 94121.

Cancer research (UNITED STATES) Feb 15 1993, 53 (4) p884-90, ISSN 0008-5472--Print Journal Code: 2984705R

Contract/Grant No.: CA24321; CA; NCI

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... of the structures of mucins may assist in the development of new therapeutic approaches. Monoclonal antibody Ea6, developed against mucins purified from xenografts of the pancreatic cancer cell line SW1990, was used to identify a new type of pancreatic cancer mucin . The following characteristics suggest that Ea6 antibody reacts with the core structure

of O-linked oligosaccharides, the Tn antigen (N-acetylgalactosamine-serine ...

... buoyant densities (1.36 versus 1.44 g/ml) than mucins identified by another monoclonal antibody directed against SW1990 mucins, SPan-1, and were less acidic. High density and molecular mass...

... bond reduction. After partial deglycosylation secreted SPan-1 antigens reacted with MUC1 peptide specific antibodies, SM - 3 and HMFG-2, as well as polyclonal antisera directed against deglycosylated xenograft mucins. However, Ea6...

... prior treatment. No Ea6 reactivity was detected with this fraction. These results suggest that Ea6 antibody identifies a new population of mucins that is distinct from SPan-1 mucins.

10/K/4 (Item 4 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2006 Dialog. All rts. reserv.

09186073 PMID: 1372533

**Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.**

Peat N; Gendler S J; Lalani N; Duhig T; Taylor-Papadimitriou J  
Imperial Cancer Research Fund, Lincoln's Inn Fields, London, England.  
Cancer research (UNITED STATES) Apr 1 1992, 52 (7) p1954-60, ISSN  
0008-5472--Print Journal Code: 2984705R  
Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

**Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.**

The human MUC1 gene codes for the core protein of a mucin which is expressed by glandular epithelia and the carcinomas which develop from these tissues. The...

... glycosylated in cancers, and some antibodies show specificity in their reactions with the cancer-associated mucin, which also contains epitopes recognized by T-cells from breast and pancreatic cancer patients. For evaluating the potential use of mucin-reactive antibodies and mucin-based immunogens in cancer patients, a mouse model, expressing the MUC1 gene product PEM (polymorphic epithelial mucin) as a self antigen, would be extremely useful. To this end, we have developed transgenic...

... gene, which was very similar to the profile of expression seen in human tissues. The antibody SM - 3 is directed to a core protein epitope, which is selectively exposed in breast cancers and...

...more restricted distribution on normal human tissues. It was established that the distribution of the SM - 3 epitope of PEM in the tissues of the transgenic mice is similar to that seen...

10/K/5 (Item 5 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2006 Dialog. All rts. reserv.

08991468 PMID: 1718981

**Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins.**

Baeckstrom D; Hansson G C; Nilsson O; Johansson C; Gendler S J; Lindholm

L

Department of Medical Biochemistry, University of Goteborg, Sweden.

Journal of biological chemistry (UNITED STATES) Nov 15 1991, 266 (32)

p21537-47, ISSN 0021-9258--Print Journal Code: 2985121R

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

**Purification and characterization of a membrane-bound and a secreted mucin -type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins.**

Two mucin -type glycoproteins detected by the monoclonal antibody C50, which reacts with the carcinoma-associated sialyl-Lewis a and sialyl-lactotetraose epitopes, were...

... glycoproteins were purified from xenograft extracts and spent culture medium using perchloric acid precipitation, monoclonal antibody affinity purification, ion exchange chromatography, and gel filtration. Both glycoproteins were unaffected by reduction and...

... of the intact glycoproteins showed that both H-CanAg and L-CanAg expressed the monoclonal antibody -defined, sialic acid-containing carbohydrate epitopes CA203 and CA242 as well as the Lewis a...

... terminal part of the MUC1 gene product, core protein of the carcinoma-associated polymorphic epithelial mucin (PEM) and DU-PAN-2, reacted with H-CanAg. After deglycosylation with trifluoromethanesulfonic acid, H-CanAg but not L-CanAg was recognized by the monoclonal antibodies SM - 3 and HMFG-2, directed to the tandem repeat of the PEM apoprotein. However, these antibodies...

10/K/6 (Item 6 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

08195471 PMID: 2477336

**A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.**

Burchell J; Taylor-Papadimitriou J; Boshell M; Gendler S; Duhig T

Imperial Cancer Research Fund, London, UK.

International journal of cancer. Journal international du cancer (UNITED STATES) Oct 15 1989, 44 (4) p691-6, ISSN 0020-7136--Print

Journal Code: 0042124

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

**A short sequence, within the amino acid tandem repeat of a cancer-associated mucin , contains immunodominant epitopes.**

The polymorphic epithelial mucin (PEM) appears to be the target

molecule for many monoclonal antibodies (MAbs) which react with...

... have precisely mapped the epitopes of 4 MAbs reactive with the tandem repeats including one, SM - 3 , which shows enhanced tumour specificity. We report that the core of the SM - 3 epitope corresponds to the continuous amino acid sequence Pro-Asp-Thr-Arg-Pro. We also...

... However, none of these epitopes contain the proline found at the amino end of the SM - 3 determinant. These results are consistent with the idea that, in the cancer-associated mucin , premature termination of the carbohydrate side-chains results in the exposure of the SM - 3 epitope.

; Amino Acid Sequence; Antibodies, Monoclonal--analysis--AN; Antigens, Tumor-Associated, Carbohydrate--immunology--IM; Binding Sites, Antibody --genetics--GE; Binding Sites, Antibody --immunology--IM; Enzyme-Linked Immunosorbent Assay; Epitopes--immunology--IM; Humans; Molecular Sequence Data; Mucins--immunology...

Chemical Name: Antibodies, Monoclonal; Antigens, Tumor-Associated, Carbohydrate; Binding Sites, Antibody ; Epitopes; Mucins; DNA

10/K/7 (Item 7 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

08087756 PMID: 2471698

**A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas.**

Girling A; Bartkova J; Burchell J; Gendler S; Gillett C; Taylor-Papadimitriou J

Imperial Cancer Research Fund Clinical Oncology Unit, Guy's Hospital, London, UK.

International journal of cancer. Journal international du cancer (UNITED STATES) Jun 15 1989, 43 (6) p1072-6, ISSN 0020-7136--Print

Journal Code: 0042124

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

**A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM - 3 is selectively exposed in a range of primary carcinomas.**

The monoclonal antibody (MAb) SM - 3 , which was raised to chemically deglycosylated milk mucin , reacts with an epitope present on the core protein of this mucin which we have referred to as PEM (polymorphic epithelial mucin ). Although this mucin is abundantly expressed by both the lactating breast and breast carcinomas, the antibody SM - 3 shows very little or no reactivity on the former but does react with 92% of breast carcinomas. Furthermore, SM - 3 stains primary carcinomas of the lung, colon and ovary, but on the corresponding normal tissue...

... level or not at all. These results indicate that an epitope masked in the normal mucin is exposed in the mucin produced by tumour cells, perhaps due to aberrant glycosylation. An extensive immunohistochemical study of other normal tissues reveals that the majority show only weak focal staining with SM - 3 or none at all, the distal tubules and collecting ducts of the kidney, and sebaceous...

10/K/8 (Item 8 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

08050539 PMID: 2469454

**Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2.**

Stacker S A; Tjandra J J; Xing P X; Walker I D; Thompson C H; McKenzie I F

Department of Pathology, University of Melbourne, Victoria, Australia.

British journal of cancer (ENGLAND) Apr 1989, 59 (4) p544-53, ISSN 0007-0920--Print Journal Code: 0370635

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

**Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2.**

... from the sera, ascites and breast carcinoma tissue of patients with breast cancer using monoclonal antibody 3E1.2. The 3E1.2 defined antigen, termed mammary serum antigen (MSA) was obtained by...

...acetyl glucosamine as indicated by its binding to wheat-germ agglutinin. The epitope defined by antibody 3E1.2 is sensitive to treatment by sodium periodate and neuraminidase, implying that both carbohydrate and sialic acid are required for binding of antibody 3E1.2. Sandwich immunoassays demonstrated that MSA+ molecules are likely to express repeated 3E1.2...

... glycoprotein. It is suggested that MSA has the same core protein as is recognised by antibody DF3 which has been used to clone the same cDNA as was cloned with antibodies HMFG-1, HMFG-2 and SM - 3. However, the epitope detected by the 3E1.2 antibody is either absent or weakly expressed on human milk, human milk-fat globule membrane (HMFGM) or deglycosylated HMFGM--all of which react strongly with various anti-HMFG antibodies. The antibody 3E1.2 thus recognises a unique epitope of the high molecular weight glycoproteins of human...

10/K/9 (Item 9 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

07447846 PMID: 2443241

**Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin.**

Burchell J; Gendler S; Taylor-Papadimitriou J; Girling A; Lewis A; Millis R; Lampert D

Imperial Cancer Research Fund, London.

Cancer research (UNITED STATES) Oct 15 1987, 47 (20) p5476-82, ISSN 0008-5472--Print Journal Code: 2984705R

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... of breast cancer reactive monoclonal antibodies directed to the core

**protein of the human milk mucin .**

A mucin molecule, which has a molecular weight of greater than 400,000 and which carries tumor...

... by affinity chromatography followed by passage through a size exclusion column. While treatment of the mucin with hydrogen fluoride for 1 h at 4 degrees C removed the peripheral oligosaccharides, treatment...

... a dominant polypeptide of about 68,000. This appears to be the size of the mucin core protein. Monoclonal antibodies have been developed that react with the stripped and partially stripped molecule but not with the intact mucin. From the initial screening on histological sections one of these antibodies, SM - 3, reacts with 91% of breast carcinomas but shows little or no reactivity on benign mammary tumors, normal resting, pregnant, or lactating breast. It appears that this monoclonal antibody is reacting with an epitope that is usually masked by oligosaccharide moieties in normal cells...

10/K/10 (Item 1 from file: 159)

DIALOG(R)File 159:Cancerlit

(c) format only 2002 Dialog. All rts. reserv.

02560227 99386938 PMID: 10455130

**Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes.**

Beum P V; Singh J; Burdick M; Hollingsworth M A; Cheng P W

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA.

J Biol Chem (UNITED STATES) Aug 27 1999, 274 (35) p24641-8, ISSN 0021-9258 Journal Code: 2985121R

Contract/Grant No.: HL48242; HL; NHLBI; P30 CA36727; CA; NCI; RO1 CA69234 ; CA; NCI

Document Type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... stable transfection of a human pancreatic adenocarcinoma cell line, Panc1-MUC1, with the cDNA for mucin core 2 GlcNAc-transferase (C2GnT), which creates the core 2 beta-1,6 branch in mucin-type glycans. These cells lack endogenous C2GnT activity but express a recombinant human MUC1 cDNA...

... clones expressing different levels of C2GnT were characterized using monoclonal antibodies CC49, CSLEX-1, and SM - 3, which recognize tumor-associated epitopes. Increased C2GnT expression led to greatly diminished expression of the...

... transfectants could not bind to selectins. Increased C2GnT expression also led to masking of the SM - 3 peptide epitope, which persisted after the removal of sialic acid, further suggesting greater complexity of...

...Chemical Name: 3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; Antibodies, Monoclonal; Antibodies, Neoplasm; B72.3 antibody ; CA-15-3 Antigen; Epitopes; Mucins; Oligosaccharides; Peptides; Polysaccharides; SM3-MUC1 peptide; N-Acetylneuraminic Acid...

10/K/11 (Item 2 from file: 159)

DIALOG(R)File 159:Cancerlit

(c) format only 2002 Dialog. All rts. reserv.

02499323 99120846 PMID: 9923971

**A short synthetic peptide (DTRPAP) induces anti-mucin (MUC-1) antibody, which is reactive with human ovarian and breast cancer cells.**

Avichezer D; Taylor-Papadimitriou J; Arnon R  
Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel.

Cancer Biochem Biophys (ENGLAND) Jun 1998, 16 (1-2) p113-28, ISSN 0305-7232 Journal Code: 7506524

Document Type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**A short synthetic peptide (DTRPAP) induces anti- mucin (MUC-1) antibody , which is reactive with human ovarian and breast cancer cells.**

The present study describes the production of a synthetic hexapeptide (DTRPAP)-based anti- mucin (MUC-1) antibody , similar to those produced using either the intact mucin antigen or tumor extracts. This antibody was generated by immunization of rabbits with the synthetic peptide conjugated to bovine serum albumin...

...a carrier. Using both the ELISA and FACS analysis methods, we have shown that the antibody is reactive with human ovarian and breast cancer cells, but not with normal epithelial breast cells. This antibody is different from the previously reported anti- mucin HMFG-1, HMFG-2 and SM - 3 monoclonal antibodies, since competitive experiments with the free synthetic peptide revealed only a 30% inhibition...

... ovarian (OVCAR-3) cancer cells, as compared to 78% inhibition of the anti-synthetic peptide antibody . The peptide was non-inhibitory for HMFG-2, and induced a significant and reproducible stimulation of the SM - 3 binding activity to the tumor cells.

Minor Descriptors: Antibodies--metabolism--ME; Antibody Specificity; Cytotoxicity, Immunologic; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Mice; Mice, Nude; Neoplasm Transplantation; Peptide...

10/K/12 (Item 3 from file: 159)

DIALOG(R)File 159:Cancerlit

(c) format only 2002 Dialog. All rts. reserv.

02060062 PMID: 94696132

**Analyses of pp60(c-src) and epidermal growth factor receptor protein tyrosine kinases in a human colon adenocarcinoma cell line following induction of goblet cell-like characteristics by tumor necrosis factor-alpha.**

Novotny-Smith

Univ. of Texas H.S.C. at Houston Grad. Sch. of Biomed. Sci.

Diss Abstr Int [B] 1993, 53 (12), ISSN 0419-4217

Document Type: THESIS

Languages: ENGLISH

Main Citation Owner: NOTNLM

Record type: Completed

... adenocarcinoma cell line is utilized as an in vitro model system in which to study mucin production. In response to treatment with tumor necrosis factor-alpha, DiFi cells acquire some properties of mucin-producing goblet cells including altered morphology, increased reactivity to wheat germ agglutinin, and increased mucin production as determined by

RNA expression as well as reactivity with the MUC-1 antibodies, HMFG-1 and SM - 3 . Thus, TNF-treated DiFi cells represent one of the few in vitro systems in which mucin expression can be induced. DiFi cells express an activated pp60(c-src), as do most...

... tyrosine phosphorylation of EGF receptor were observed as assessed by immunoblotting with an anti-phosphotyrosine antibody . In addition, [125I]-EGF cell surface binding was reduced approximately 3-fold following TNF treatment...

Chemical Name: Proto-Oncogene Protein pp60(c-src; Protein-Tyrosine Kinase ; polymorphic epithelial mucin ; Antibodies; Mucins; Receptors, Epidermal Growth Factor-Urogastrone; Tumor Necrosis Factor

10/K/13 (Item 4 from file: 159)  
DIALOG(R)File 159:Cancerlit  
(c) format only 2002 Dialog. All rts. reserv.

01990334 93153790 PMID: 7679052

**Multiple forms of intracellular and secreted mucins in a pancreatic cancer cell line.**

Ho J J; Bi N; Siddiki B; Chung Y S; Yuan M; Kim Y S  
Gastrointestinal Research Laboratory, Veterans Affairs Medical Center, San Francisco, California 94121.  
Cancer Res (UNITED STATES) Feb 15 1993, 53 (4) p884-90, ISSN 0008-5472 Journal Code: 2984705R  
Contract/Grant No.: CA24321; CA; NCI  
Document Type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: Completed

... of the structures of mucins may assist in the development of new therapeutic approaches. Monoclonal antibody Ea6, developed against mucins purified from xenografts of the pancreatic cancer cell line SW1990, was used to identify a new type of pancreatic cancer mucin . The following characteristics suggest that Ea6 antibody reacts with the core structure of O-linked oligosaccharides, the Tn antigen (N-acetylgalactosamine-serine ...

... buoyant densities (1.36 versus 1.44 g/ml) than mucins identified by another monoclonal antibody directed against SW1990 mucins, SPan-1, and were less acidic. High density and molecular mass...

... bond reduction. After partial deglycosylation secreted SPan-1 antigens reacted with MUC1 peptide specific antibodies, SM - 3 and HMFG-2, as well as polyclonal antisera directed against deglycosylated xenograft mucins. However, Ea6...

... prior treatment. No Ea6 reactivity was detected with this fraction. These results suggest that Ea6 antibody identifies a new population of mucins that is distinct from SPan-1 mucins.

10/K/14 (Item 5 from file: 159)  
DIALOG(R)File 159:Cancerlit  
(c) format only 2002 Dialog. All rts. reserv.

01924587 92200415 PMID: 1372533

**Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.**



Peat N; Gendler S J; Lalani N; Duhig T; Taylor-Papadimitriou J  
Imperial Cancer Research Fund, Lincoln's Inn Fields, London, England.  
Cancer Res (UNITED STATES) Apr 1 1992, 52 (7) p1954-60, ISSN  
0008-5472 Journal Code: 2984705R  
Document Type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: Completed

**Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.**

The human MUC1 gene codes for the core protein of a mucin which is expressed by glandular epithelia and the carcinomas which develop from these tissues. The...

... glycosylated in cancers, and some antibodies show specificity in their reactions with the cancer-associated mucin, which also contains epitopes recognized by T-cells from breast and pancreatic cancer patients. For evaluating the potential use of mucin-reactive antibodies and mucin-based immunogens in cancer patients, a mouse model, expressing the MUC1 gene product PEM (polymorphic epithelial mucin) as a self antigen, would be extremely useful. To this end, we have developed transgenic...

... gene, which was very similar to the profile of expression seen in human tissues. The antibody SM - 3 is directed to a core protein epitope, which is selectively exposed in breast cancers and...

...more restricted distribution on normal human tissues. It was established that the distribution of the SM - 3 epitope of PEM in the tissues of the transgenic mice is similar to that seen...

10/K/15 (Item 6 from file: 159)  
DIALOG(R)File 159:Cancerlit  
(c) format only 2002 Dialog. All rts. reserv.

01891633 92042052 PMID: 1718981  
**Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins.**

Baeckstrom D; Hansson G C; Nilsson O; Johansson C; Gendler S J; Lindholm L

Department of Medical Biochemistry, University of Goteborg, Sweden.  
J Biol Chem (UNITED STATES) Nov 15 1991, 266 (32) p21537-47, ISSN  
0021-9258 Journal Code: 2985121R  
Document Type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: Completed

**Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins.**

Two mucin-type glycoproteins detected by the monoclonal antibody C50, which reacts with the carcinoma-associated sialyl-Lewis a and sialyl-lactotetraose epitopes, were...

... glycoproteins were purified from xenograft extracts and spent culture medium using perchloric acid precipitation, monoclonal antibody affinity purification, ion exchange chromatography, and gel filtration. Both glycoproteins were unaffected by reduction and...

... of the intact glycoproteins showed that both H-CanAg and L-CanAg expressed the monoclonal antibody -defined, sialic acid-containing carbohydrate epitopes CA203 and CA242 as well as the Lewis a...

... terminal part of the MUC1 gene product, core protein of the carcinoma-associated polymorphic epithelial mucin (PEM) and DU-PAN-2, reacted with H-CanAg. After deglycosylation with trifluoromethanesulfonic acid, H-CanAg but not L-CanAg was recognized by the monoclonal antibodies SM - 3 and HMFG-2, directed to the tandem repeat of the PEM apoprotein. However, these antibodies...

10/K/16 (Item 7 from file: 159)  
DIALOG(R)File 159:Cancerlit  
(c) format only 2002 Dialog. All rts. reserv.

01781134 PMID: 91668429

**EPITHELIAL MUCIN ANTIBODIES AND THEIR EPITOPES: CORE PROTEIN EPITOPES OF A POLYMORPHIC EPITHELIAL MUCIN (PEM).**

Taylor-Papadimitriou; Burchell; Gendler; Boshell; Duhig  
Imperial Cancer Res. Fund, P.O. Box 123, Lincoln's Inn Fields, London WC2A 3PX, UK

Non-serial 1989, Breast Cancer Immunodiagnosis and Immunotherapy. Ceriani RL, ed. New York, Plenum, p. 81-93, 1989.,

Document Type: MEETING PAPER

Languages: ENGLISH

Main Citation Owner: NOTNLM

Record type: Completed

**EPITHELIAL MUCIN ANTIBODIES AND THEIR EPITOPES: CORE PROTEIN EPITOPES OF A POLYMORPHIC EPITHELIAL MUCIN (PEM).**

Data have been obtained recently from a human mucin that is expressed by several simple epithelial cell types and abundantly by the lactating mammary gland and by many carcinomas. This mucin, called PEM because of the high degree of polymorphism seen at the DNA and protein...

... PEM repeat unit exhibit features that would be expected in the core protein of a mucin. There are five potential O glycosylation sites represented by serines and threonines separated by proline-rich stretches of 3, 5, and 7 AAs. The enhanced tumor specificity of the antibody SM - 3 directed to the deglycosylated PEM indicates that the epitopes to the core protein, which normally are masked, can be exposed in the cancer-associated mucin (CAM). Thus, at least some of the difference between the normally processed mucin and the mucin expressed in breast cancers may be due to differences in glycosylation patterns. The exposure of core protein epitopes in the cancer mucin could be due to underglycosylation of potential glycosylation sites or to a reduction in the length of the added oligosaccharide side chains. The mapping of the SM - 3 and HMFG-2 epitopes to AAs around a threonine residue in the tandem repeat sequence...

... for shorter oligosaccharide side chains on the CAM is provided by the observation that the SM - 3 epitope, which is only exposed in this form of the mucin, contains extra AAs flanking the HMFG-2 epitope, some of which apparently are masked in...

10/K/17 (Item 8 from file: 159)  
DIALOG(R)File 159:Cancerlit

(c) format only 2002 Dialog. All rts. reserv.

01752977 90007760 PMID: 2477336

**A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.**

Burchell J; Taylor-Papadimitriou J; Boshell M; Gendler S; Duhig T  
Imperial Cancer Research Fund, London, UK.

Int J Cancer (UNITED STATES) Oct 15 1989, 44 (4) p691-6, ISSN  
0020-7136 Journal Code: 0042124

Document Type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.**

The polymorphic epithelial mucin (PEM) appears to be the target molecule for many monoclonal antibodies (MAbs) which react with...

... have precisely mapped the epitopes of 4 MAbs reactive with the tandem repeats including one, SM - 3, which shows enhanced tumour specificity. We report that the core of the SM - 3 epitope corresponds to the continuous amino acid sequence Pro-Asp-Thr-Arg-Pro. We also...

... However, none of these epitopes contain the proline found at the amino end of the SM - 3 determinant. These results are consistent with the idea that, in the cancer-associated mucin, premature termination of the carbohydrate side-chains results in the exposure of the SM - 3 epitope.

Minor Descriptors: Amino Acid Sequence; Antibodies, Monoclonal--analysis--AN; Antigens, Tumor-Associated, Carbohydrate--immunology--IM; Binding Sites, Antibody --genetics--GE; Binding Sites, Antibody --immunology--IM; Enzyme-Linked Immunosorbent Assay; Epitopes--immunology--IM; Molecular Sequence Data; Mucins--immunology--IM...

Chemical Name: Antibodies, Monoclonal; Antigens, Tumor-Associated, Carbohydrate; Binding Sites, Antibody; Epitopes; Mucins; DNA

10/K/18 (Item 9 from file: 159)

DIALOG(R)File 159:Cancerlit

(c) format only 2002 Dialog. All rts. reserv.

01734841 89277584 PMID: 2471698

**A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas.**

Girling A; Bartkova J; Burchell J; Gendler S; Gillett C;  
Taylor-Papadimitriou J  
Imperial Cancer Research Fund Clinical Oncology Unit, Guy's Hospital,  
London, UK.

Int J Cancer (UNITED STATES) Jun 15 1989, 43 (6) p1072-6, ISSN  
0020-7136 Journal Code: 0042124

Document Type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM - 3 is selectively exposed in a range of primary carcinomas.**

The monoclonal antibody (MAb) SM - 3, which was raised to chemically deglycosylated milk mucin, reacts with an epitope present on the core

protein of this mucin which we have referred to as PEM (polymorphic epithelial mucin). Although this mucin is abundantly expressed by both the lactating breast and breast carcinomas, the antibody SM - 3 shows very little or no reactivity on the former but does react with 92% of breast carcinomas. Furthermore, SM - 3 stains primary carcinomas of the lung, colon and ovary, but on the corresponding normal tissue...

... level or not at all. These results indicate that an epitope masked in the normal mucin is exposed in the mucin produced by tumour cells, perhaps due to aberrant glycosylation. An extensive immunohistochemical study of other normal tissues reveals that the majority show only weak focal staining with SM - 3 or none at all, the distal tubules and collecting ducts of the kidney, and sebaceous...

10/K/19 (Item 10 from file: 159)

DIALOG(R)File 159:Cancerlit

(c) format only 2002 Dialog. All rts. reserv.

01728393 89228880 PMID: 2469454

**Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2.**

Stacker S A; Tjandra J J; Xing P X; Walker I D; Thompson C H; McKenzie I F

Department of Pathology, University of Melbourne, Victoria, Australia.

Br J Cancer (ENGLAND) Apr 1989, 59 (4) p544-53, ISSN 0007-0920

Journal Code: 0370635

Document Type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2.**

... from the sera, ascites and breast carcinoma tissue of patients with breast cancer using monoclonal antibody 3E1.2. The 3E1.2 defined antigen, termed mammary serum antigen (MSA) was obtained by...

...acetyl glucosamine as indicated by its binding to wheat-germ agglutinin. The epitope defined by antibody 3E1.2 is sensitive to treatment by sodium periodate and neuraminidase, implying that both carbohydrate and sialic acid are required for binding of antibody 3E1.2. Sandwich immunoassays demonstrated that MSA+ molecules are likely to express repeated 3E1.2...

... glycoprotein. It is suggested that MSA has the same core protein as is recognised by antibody DF3 which has been used to clone the same cDNA as was cloned with antibodies HMFG-1, HMFG-2 and SM - 3. However, the epitope detected by the 3E1.2 antibody is either absent or weakly expressed on human milk, human milk-fat globule membrane (HMFGM) or deglycosylated HMFGM--all of which react strongly with various anti-HMFG antibodies. The antibody 3E1.2 thus recognises a unique epitope of the high molecular weight glycoproteins of human...

10/K/20 (Item 11 from file: 159)

DIALOG(R)File 159:Cancerlit

(c) format only 2002 Dialog. All rts. reserv.

01629625 88002032 PMID: 2443241

**Development and characterization of breast cancer reactive monoclonal**

**antibodies directed to the core protein of the human milk mucin.**

Burchell J; Gendler S; Taylor-Papadimitriou J; Girling A; Lewis A; Millis R; Lampport D

Imperial Cancer Research Fund, London.

Cancer Res (UNITED STATES) Oct 15 1987, 47 (20) p5476-82, ISSN 0008-5472 Journal Code: 2984705R

Document Type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**... of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin .**

A mucin molecule, which has a molecular weight of greater than 400,000 and which carries tumor...

... by affinity chromatography followed by passage through a size exclusion column. While treatment of the mucin with hydrogen fluoride for 1 h at 4 degrees C removed the peripheral oligosaccharides, treatment...

... a dominant polypeptide of about 68,000. This appears to be the size of the mucin core protein. Monoclonal antibodies have been developed that react with the stripped and partially stripped molecule but not with the intact mucin . From the initial screening on histological sections one of these antibodies, SM - 3 , reacts with 91% of breast carcinomas but shows little or no reactivity on benign mammary tumors, normal resting, pregnant, or lactating breast. It appears that this monoclonal antibody is reacting with an epitope that is usually masked by oligosaccharide moieties in normal cells...

10/K/21 (Item 1 from file: 35)

DIALOG(R)File 35:Dissertation Abs Online

(c) 2006 ProQuest Info&Learning. All rts. reserv.

01284950 ORDER NO: AAD93-12171

**ANALYSES OF PP60(C-SRC) AND EPIDERMAL GROWTH FACTOR RECEPTOR PROTEIN TYROSINE KINASES IN A HUMAN COLON ADENOCARCINOMA CELL LINE FOLLOWING INDUCTION OF GOBLET CELL-LIKE CHARACTERISTICS BY TUMOR NECROSIS FACTOR-ALPHA ( PP60(C SRC))**

Author: NOVOTNY-SMITH, CATHERINE LYNN

Degree: PH.D.

Year: 1992

Corporate Source/Institution: THE UNIV. OF TEXAS H.S.C. AT HOUSTON GRAD. SCH. OF BIOMED. SCI. (2034)

Source: VOLUME 53/12-B OF DISSERTATION ABSTRACTS INTERNATIONAL. PAGE 6090. 295 PAGES

...adenocarcinoma cell line is utilized as an in vitro model system in which to study mucin production. In response to treatment with tumor necrosis factor-alpha, DiFi cells acquire some properties of mucin-producing goblet cells including altered morphology, increased reactivity to wheat germ agglutinin, and increased mucin production as determined by RNA expression as well as reactivity with the MUC-1 antibodies, HMFG-1 and SM - 3 . Thus, TNF-treated DiFi cells represent one of the few in vitro systems in which mucin expression can be induced.

DiFi cells express an activated pp60 $\{c\}$ -src,\$ as...

...tyrosine phosphorylation of EGF receptor were observed as assessed by immunoblotting with an anti-phosphotyrosine antibody . In addition, ( $\{^{125}I\}$ )-EGF cell surface binding was reduced approximately 3-fold

following...

10/K/22 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0013644280 BIOSIS NO.: 200200237791  
**NMR-based determination of the binding epitope and conformational analysis of MUC-1 glycopeptides and peptides bound to the breast cancer-selective monoclonal antibody SM3**  
AUTHOR: Moeller Heiko; Serttas Nida; Paulsen Hans; Burchell Joy M;  
Taylor-Papadimitriou Joyce; Meyer Bernd (Reprint)  
AUTHOR ADDRESS: Institute of Organic Chemistry, University of Hamburg,  
Martin-Luther-King-Platz 6, 20146, Hamburg, Germany\*\*Germany  
JOURNAL: European Journal of Biochemistry 269 (5): p1444-1455 March, 2002  
2002  
MEDIUM: print  
ISSN: 0014-2956  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

**...conformational analysis of MUC-1 glycopeptides and peptides bound to the breast cancer-selective monoclonal antibody SM3**

ABSTRACT: Mucin glycoproteins on breast cancer cells carry shortened carbohydrate chains. These partially deglycosylated mucin 1 (MUC-1) structures are recognized by the monoclonal antibody SM3, which is being tested for its diagnostic utility. We used NMR spectroscopy to analyze the binding mode and the binding epitope of peptide and glycopeptide antigens to the SM3 antibody. The pentapeptide PDTRP and the glycopentapeptide PDT(O-alpha-D-GalNAc)RP are known ligands of the monoclonal antibody. The 3D structures of the ligands in the bound conformation were determined by analyzing trNOESY...

...was found to adopt an extended conformation that fits into the binding pocket of the antibody. The binding epitopes of the ligands were determined by saturation transfer difference (STD) NMR spectroscopy...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: MUC-1 mucin glycopeptides...

...3-dimensional structure, binding epitope determination, conformational analysis, tumor expression, tumor selective SM - 3 monoclonal antibody binding...

...MUC-1 mucin peptides...

...3-dimensional structure, binding epitope determination, conformational analysis, tumor expression, tumor selective SM - 3 monoclonal antibody binding

10/K/23 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0011835278 BIOSIS NO.: 199900094938  
**Evaluation of Pepscan analyses for epitope mapping of anti-MUC1 monoclonal antibodies: A comparative study and review of five antibodies**

AUTHOR: Petrakou Eftichia (Reprint); Murray Andrea; Rosamund C; Graves L;  
Price Michael R  
AUTHOR ADDRESS: Cancer Res. Lab., Univ. Nottingham, Nottingham NG7 2RD, UK  
\*\*UK  
JOURNAL: Anticancer Research 18 (6A): p4419-4422 Nov.-Dec., 1998 1998  
MEDIUM: print  
ISSN: 0250-7005  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Many murine monoclonal antibodies against MUC1 mucin have been analysed for reactivity against short overlapping peptides with sequences based upon that of...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: C-595 anti-MUC-1 monoclonal antibody ----  
...DF-3 anti-MUC-1 monoclonal antibody ----  
...HMFG-1 anti-MUC-1 monoclonal antibody ----  
...Ma-552 anti-MUC-1 monoclonal antibody ----  
... SM - 3 anti-MUC-1 monoclonal antibody --

10/K/24 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0009863463 BIOSIS NO.: 199598331296

**Access to peptide regions of a surface mucin (MUC1) is reduced by sialic acids**

AUTHOR: Ho Jenny J L; Cheng Sandra; Kim Y S  
AUTHOR ADDRESS: Gastrointestinal Res. Lab., Veterans Affairs Med. Cent.,  
San Francisco, CA 94121, USA\*\*USA  
JOURNAL: Biochemical and Biophysical Research Communications 210 (3): p  
866-873 1995 1995  
ISSN: 0006-291X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

**Access to peptide regions of a surface mucin (MUC1) is reduced by sialic acids**

...ABSTRACT: glycoproteins are present on the surfaces of tumor cells. Knowledge of which parts of the mucin molecule are accessible targets for cells of the immune system is important in the development...  
...specific for the tripeptide (DTR) in the 20 amino acid tandem repeat of MUC1, and SM - 3 (PDTRP) were greatly enhanced by pre-treating cells with an inhibitor of Oglycosylation, benzyl-alpha...  
...with an inhibitor of carbohydrate processing, monensin, also greatly enhanced the reactivities of HMFG-2, SM - 3 and HMFG-1 (PDTR). Thus, sialic acids on termini of neighboring oligosaccharides significantly limit access to the peptide region recognized by antibodies HMFG-1/2 and SM - 3 .  
DESCRIPTORS:

MISCELLANEOUS TERMS: ANTIBODY ACCESSIBILITY...

10/K/25 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0008807949 BIOSIS NO.: 199395110215

**Multiple forms of intracellular and secreted mucins in a pancreatic cancer cell line**

AUTHOR: Ho Jenny J L (Reprint); Bi Ning; Siddiki Bader; Chung Yong-Suk;  
Yuan Mei; Kim Young S

AUTHOR ADDRESS: GI Research Lab., Veterans Affairs Med. Center, 4150  
Clement St., San Francisco, CA 94121, USA\*\*USA

JOURNAL: Cancer Research 53 (4): p884-890 1993

ISSN: 0008-5472

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: of the structures of mucins may assist in the development of new therapeutic approaches. Monoclonal antibody Ea6, developed against mucins purified from xenografts of the pancreatic cancer cell line SW1990, was used to identify a new type of pancreatic cancer mucin. The following characteristics suggest that Ea6 antibody reacts with the core structure of O-linked oligosaccharides, the Tn antigen (N-acetylgalactosamine-serine...

...buoyant densities (1.36 versus 1.44 g/ml) than mucins identified by another monoclonal antibody directed against SW1990 mucins, SPan-1, and were less acidic. High density and molecular mass...

...bond reduction. After partial deglycosylation secreted SPan-1 antigens reacted with MUC1 peptide specific antibodies, SM - 3 and HMFG-2, as well as polyclonal antisera directed against deglycosylated xenograft mucins. However, Ea6...

...prior treatment. No Ea6 reactivity was detected with this fraction. These results suggest that Ea6 antibody identifies a new population of mucins that is distinct from SPan-1 mucins.

10/K/26 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0008305424 BIOSIS NO.: 199294007265

**TISSUE-SPECIFIC EXPRESSION OF A HUMAN POLYMORPHIC EPITHELIAL MUCIN MUC1 IN TRANSGENIC MICE**

AUTHOR: PEAT N (Reprint); GENDLER S J; LALANI E-N; DUHIG T;  
TAYLOR-PAPADIMITRIOU J

AUTHOR ADDRESS: IMPERIAL CANCER RES FUND, PO BOX 123, LINCOLN'S INN FIELDS,  
LONDON WC2A 3PX, ENGLAND, UK\*\*UK

JOURNAL: Cancer Research 52 (7): p1954-1960 1992

ISSN: 0008-5472

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

**TISSUE-SPECIFIC EXPRESSION OF A HUMAN POLYMORPHIC EPITHELIAL MUCIN MUC1 IN TRANSGENIC MICE**



ABSTRACT: The human MUC1 gene codes for the core protein of a mucin which is expressed by glandular epithelia and the carcinomas which develop from these tissues. The...

...glycosylated in cancers, and some antibodies show specificity in their reactions with the cancer-associated mucin, which also contains epitopes recognized by T-cells from breast and pancreatic cancer patients. For evaluating the potential use of mucin-reactive antibodies and mucin-based immunogens in cancer patients, a mouse model, expressing the MUC1 gene product PEM (polymorphic epithelial mucin) as a self antigen, would be extremely useful. To this end, we have developed transgenic...

...gene, which was very similar to the profile of expression seen in human tissues. The antibody SM - 3 is directed to a core protein epitope, which is selectively exposed in breast cancers and...

...more restricted distribution on normal human tissues. It was established that the distribution of the SM - 3 epitope of PEM in the tissues of the transgenic mice is similar to that seen...

10/K/27 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0008187468 BIOSIS NO.: 199293030359

**PURIFICATION AND CHARACTERIZATION OF A MEMBRANE-BOUND AND A SECRETED MUCIN-TYPE GLYCOPROTEIN CARRYING THE CARCINOMA-ASSOCIATED SIALYL-LE-A EPI TOPE ON DISTINCT CORE PROTEINS**

AUTHOR: BAECKSTROM D (Reprint); HANSSON G C; NILSSON O; JOHANSSON C; GENDLER S J; LINDHOLM L

AUTHOR ADDRESS: DEP MEDICAL BIOCHEMISTRY, UNIVERSITY GOTEBOG, BOX 33031, S-400 33 GOTEBOG, SWED\*\*SWEDEN

JOURNAL: Journal of Biological Chemistry 266 (32): p21537-21547 1991

ISSN: 0021-9258

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

**PURIFICATION AND CHARACTERIZATION OF A MEMBRANE-BOUND AND A SECRETED MUCIN -TYPE GLYCOPROTEIN CARRYING THE CARCINOMA-ASSOCIATED SIALYL-LE-A EPI TOPE ON DISTINCT CORE PROTEINS**

ABSTRACT: Two mucin-type glycoproteins detected by the monoclonal antibody C50, which reacts with the carcinoma-associated sialyl-Lewis a and sialyl-lactotetraose epitopes, were...

...glycoproteins were purified from xenograft extracts and spent culture medium using perchloric acid precipitation, monoclonal antibody affinity purification, ion exchange chromatography, and gel filtration. Both glycoproteins were unaffected by reduction and...

...of the intact glycoproteins showed that both H-CanAg and L-CanAg expressed the monoclonal antibody-defined, sialic acid-containing carbohydrate epitopes CA203 and CA242 as well as the Lewis a...

...terminal part of the MUC1 gene product, core protein of the carcinoma-associated polymorphic epithelial mucin (PEM) and DU-PAN-2, reacted with H-CanAg. After deglycosylation with trifluoromethanesulfonic

acid, H-CanAg but not L-CanAg was recognized by the monoclonal antibodies SM - 3 and HMFG-2, directed to the tandem repeat of the PEM apoprotein. However, these antibodies...

10/K/28 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0008005973 BIOSIS NO.: 199242108864  
**EXPRESSION OF THE CORE PROTEIN OF POLYMORPHIC EPITHELIAL MUCIN AS DETECTED BY SM-3 ANTIBODY IN PULMONARY ADENOCARCINOMA AND PLEURAL MALIGNANT MESOTHELIOMA**  
AUTHOR: SOOHOO W E J (Reprint); ORDONEZ N G  
AUTHOR ADDRESS: UNIV TEX MD ANDERSON CANCER CENT, HOUSTON, TEX, USA\*\*USA  
JOURNAL: Laboratory Investigation 66 (1): p116A 1992  
CONFERENCE/MEETING: 1992 ANNUAL MEETING OF THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, ATLANTA, GEORGIA, USA, MARCH 14-20, 1992. LAB INVEST.  
ISSN: 0023-6837  
DOCUMENT TYPE: Meeting  
RECORD TYPE: Citation  
LANGUAGE: ENGLISH

**EXPRESSION OF THE CORE PROTEIN OF POLYMORPHIC EPITHELIAL MUCIN AS DETECTED BY SM - 3 ANTIBODY IN PULMONARY ADENOCARCINOMA AND PLEURAL MALIGNANT MESOTHELIOMA**

10/K/29 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0007210549 BIOSIS NO.: 199089128440  
**THE LOCUS OF THE POLYMORPHIC EPITHELIAL MUCIN PEM TUMOR ANTIGEN ON CHROMOSOME 1Q21 SHOWS A HIGH FREQUENCY OF ALTERATION IN PRIMARY HUMAN BREAST TUMORS**  
AUTHOR: GENDLER S J (Reprint); COHEN E P; CRASTON A; DUHIG T; JOHNSTONE G; BARNES D  
AUTHOR ADDRESS: IMPERIAL CANCER RES FUND, PO BOX 123, LINCOLN'S INN FIELDS, LONDON WC2A 3PX, UK\*\*UK  
JOURNAL: International Journal of Cancer 45 (3): p431-435 1990  
ISSN: 0020-7136  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

**THE LOCUS OF THE POLYMORPHIC EPITHELIAL MUCIN PEM TUMOR ANTIGEN ON CHROMOSOME 1Q21 SHOWS A HIGH FREQUENCY OF ALTERATION IN PRIMARY HUMAN...**

...ABSTRACT: were examined for chromosome I loss of heterozygosity using a probe for a polymorphic epithelial mucin, PEM, which is expressed in > 92% of breast carcinomas as well as in normal lactating breast tissue. Expression is detected by the monoclonal antibodies (MAbs) HMFG-1, -2 and SM - 3 which react with epitopes in the 20 amino-acid repeat unit of the core protein...

DESCRIPTORS: BREAST CANCER BREAST CARCINOMA DISEASE PROGRESSION  
CYTOGENETICS MONOCLONAL ANTIBODY SOUTHERN BLOT ANALYSIS

10/K/30 (Item 9 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0006736519 BIOSIS NO.: 198988051634

**A CORE PROTEIN EPITOPE OF THE POLYMORPHIC EPITHELIAL MUCIN DETECTED BY THE MONOCLONAL ANTIBODY SM-3 IS SELECTIVELY EXPOSED IN A RANGE OF PRIMARY CARCINOMAS**

AUTHOR: GIRLING A (Reprint); BARTKOVA J; BURCHELL J; GENDLER S; GILLETT C;  
TAYLOR-PAPADIMITRIOU J

AUTHOR ADDRESS: IMPERIAL CANCER RES FUND CLINICAL ONCOL UNIT, GUY'S HOSP,  
LONDON SE1 9RT, UK\*\*UK

JOURNAL: International Journal of Cancer 43 (6): p1072-1076 1989

ISSN: 0020-7136

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

**A CORE PROTEIN EPITOPE OF THE POLYMORPHIC EPITHELIAL MUCIN DETECTED BY THE MONOCLONAL ANTIBODY SM - 3 IS SELECTIVELY EXPOSED IN A RANGE OF PRIMARY CARCINOMAS**

ABSTRACT: The monoclonal antibody (Mab) SM - 3 , which was raised to chemically deglycosylated milk mucin , reacts with an epitope present on the core protein of this mucin which we have referred to as PEM (polymorphic epithelial mucin ). Although this mucin is abundantly expressed by both the lactating breast and breast carcinomas, the antibody SM - 3 shows very little or no reactivity on the former but does react with 92% of breast carcinomas. Furthermore, SM - 3 stains primary carcinomas of the lung, colon and ovary, but on the corresponding normal tissue...

...level or not at all. These results indicate that an epitope masked in the normal mucin is exposed in the mucin produced by tumour cells, perhaps due to aberrant glycosylation. An extensive immunohistochemical study of other normal tissues reveals that the majority show only weak focal staining with SM - 3 or none at all, the distal tubules and collecting ducts of the kidney, and sebaceous...

10/K/31 (Item 10 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0006702079 BIOSIS NO.: 198988017194

**PURIFICATION AND BIOCHEMICAL CHARACTERIZATION OF A NOVEL BREAST CARCINOMA ASSOCIATED MUCIN-LIKE GLYCOPROTEIN DEFINED BY ANTIBODY 3E1.2**

AUTHOR: STACKER S A (Reprint); TJANDRA J J; XING P-X; WALKER I D; THOMPSON C H; MCKENZIE I F C

AUTHOR ADDRESS: RES CENTRE CANCER AND TRANSPLANTATION, DEP PATHOLOGY, UNIV MELBOURNE, PARKVILLE, 3052 VICTORIA, AUSTRALIA\*\*AUSTRALIA

JOURNAL: British Journal of Cancer 59 (4): p545-553 1989

ISSN: 0007-0920

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

**PURIFICATION AND BIOCHEMICAL CHARACTERIZATION OF A NOVEL BREAST CARCINOMA ASSOCIATED MUCIN -LIKE GLYCOPROTEIN DEFINED BY ANTIBODY 3E1.2**

...ABSTRACT: from the sera, ascites and breast carcinoma tissue of patients

with breast cancer using monoclonal antibody 3E1.2. The 3E1.2 defined antigen, termed mammary serum antigen (MSA) was obtained by...

...acetyl glucosamine as indicated by its binding to wheat-germ agglutinin. The epitope defined by antibody 3E1.2 is sensitive to treatment by sodium periodate and neuraminidase, implying that both carbohydrate and sialic acid are required for binding of antibody 3E1.2. Sandwich immunoassays demonstrated that MSA+ molecules are likely to express repeated 3E1.2...

...glycoprotein. It is suggested that MSA has the same core protein as is recognised by antibody DF3 which has been used to clone the same cDNA as was cloned with antibodies HMEG-1, HMFG-2 and SM - 3. However, the epitope detected by the 3E1.2 antibody is either absent or weakly expressed on human milk, human milk-fat globule membrane (HMFGM) or deglycosylated HMFGM- all of which react strongly with various anti-HMFG antibodies. The antibody 3E1.2 thus recognises a unique epitope of the high molecular weight glycoproteins of human...

DESCRIPTORS: HUMAN MAMMARY SERUM ANTIGEN TUMOR-ASSOCIATED ANTIGEN ASCITES  
BREAST CANCER TISSUE MURINE MONOCLONAL ANTIBODY SANDWICH ELISA

10/K/32 (Item 11 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0006037446 BIOSIS NO.: 198885006337

**DEVELOPMENT AND CHARACTERIZATION OF BREAST CANCER REACTIVE MONOCLONAL ANTIBODIES DIRECTED TO THE CORE PROTEIN OF THE HUMAN MILK MUCIN**

AUTHOR: BURCHELL J (Reprint); GENDLER S; TAYLOR-PAPADIMITRIOU J; GIRLING A; LEWIS A; MILLIS R; LAMPORT D

AUTHOR ADDRESS: IMPERIAL CANCER RES FUND, PO BOX 123, LINCOLN'S INN FIELDS, LONDON WC2A 3PX, UK\*\*UK

JOURNAL: Cancer Research 47 (20): p5476-5482 1987

ISSN: 0008-5472

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

**...OF BREAST CANCER REACTIVE MONOCLONAL ANTIBODIES DIRECTED TO THE CORE PROTEIN OF THE HUMAN MILK MUCIN**

ABSTRACT: A mucin molecule, which has a molecular weight of greater than 400,000 and which carries tumor...

...by affinity chromatography followed by passage through a size exclusion column. While treatment of the mucin with hydrogen fluoride for 1 h at 4.degree. C removed the peripheral oligosaccharides, treatment...

...a dominant polypeptide of about 68,000. This appears to be the size of the mucin core protein. Monoclonal antibodies have been developed that react with the stripped and partially stripped molecule but not with the intact mucin. From the initial screening on histological sections one of these antibodies, SM - 3, reacts with 91% of breast carcinomas but shows little or no reactivity on benign mammary tumors, normal resting, pregnant, or lactating breast. It appears that this monoclonal antibody is reacting with an epitope that is usually masked by oligosaccharide moieties in normal cells...

10/K/33 (Item 12 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0006010260 BIOSIS NO.: 198835107365

**EXPRESSION OF A POLYMORPHIC GENE CODING FOR AN EPITHELIAL MUCIN IN BREAST AND OTHER CARCINOMAS**

AUTHOR: TAYLOR-PAPADIMITRIOU J (Reprint); GENDLER S J; BURCHELL J  
AUTHOR ADDRESS: IMPERIAL CANCER RES FUND, PO BOX 123, LINCOLN'S INN FIELDS,  
LONDON WC2A 3PX, UK\*\*UK  
JOURNAL: Journal of Cellular Biochemistry Supplement (12 PART E): p119 1988  
CONFERENCE/MEETING: SYMPOSIUM ON HUMAN TUMOR ANTIGENS AND SPECIFIC TUMOR  
THERAPY HELD AT THE 17TH ANNUAL UCLA (UNIVERSITY OF CALIFORNIA-LOS ANGELES)  
SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY, KEYSTONE, COLORADO, USA, APRIL  
23-30, 1988. J CELL BIOCHEM.  
ISSN: 0733-1959  
DOCUMENT TYPE: Meeting  
RECORD TYPE: Citation  
LANGUAGE: ENGLISH

**EXPRESSION OF A POLYMORPHIC GENE CODING FOR AN EPITHELIAL MUCIN IN BREAST AND OTHER CARCINOMAS**

DESCRIPTORS: ABSTRACT MONOCLONAL ANTIBODY SM - 3 DIAGNOSIS  
ANTINEOPLASTIC THERAPY

10/K/34 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2006 Elsevier Science B.V. All rts. reserv.

07812092 EMBASE No: 1999301656

**Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes**

Beum P.V.; Singh J.; Burdick M.; Hollingsworth M.A.; Cheng P.-W.  
P.-W. Cheng, Dept. of Biochem./Molecular Biology, University of Nebraska  
Med. Center, 984525 Nebraska Medical Center, Omaha, NE 68198-4525 United  
States  
AUTHOR EMAIL: pcheng@unmc.edu  
Journal of Biological Chemistry ( J. BIOL. CHEM. ) (United States) 27  
AUG 1999, 274/35 (24641-24648)  
CODEN: JBCHA ISSN: 0021-9258  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 50

...stable transfection of a human pancreatic adenocarcinoma cell line, Panc1-MUC1, with the cDNA for mucin core 2 GlcNAc-transferase (C2GnT), which creates the core 2 beta-1,6 branch in mucin -type glycans. These cells lack endogenous C2GnT activity but express a recombinant human MUC1 cDNA...

...clones expressing different levels of C2GnT were characterized using monoclonal antibodies CC49, CSLEX-1, and SM - 3, which recognize tumor-associated epitopes. Increased C2GnT expression led to greatly diminished expression of the...

...transfectants could not bind to selectins. Increased C2GnT expression also led to masking of the SM - 3 peptide epitope, which persisted after the removal of sialic acid, further suggesting greater complexity of...  
DRUG DESCRIPTORS:

complementary DNA; mucin ; glycan; monoclonal antibody ; selectin; sialic acid; ligand

10/K/35 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2006 Elsevier Science B.V. All rts. reserv.

06219800 EMBASE No: 1995248438  
**Association of sialyl-Lewis x and sialyl-Lewis (x) with MUC-1 apomucin in a pancreatic cancer cell line**  
Ho J.J.L.; Siddiki B.; Kim Y.S.  
Veterans Administration Medical Ctr., University of California, 4150  
Clement Street, San Francisco, CA 94121 United States  
Cancer Research ( CANCER RES. ) (United States) 1995, 55/16 (3659-3663)  
CODEN: CNREA ISSN: 0008-5472  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

...by neuraminidase greatly enhanced binding of two other MUC1 peptide specific antibodies, HMFG-2 and SM - 3 . After removal of sialic acids, most of the mucins rich in sialyl-Lewis x and...

DRUG DESCRIPTORS:

\* mucin ; \*sialic acid  
carbohydrate; lectin; monoclonal antibody ; polyclonal antibody ;  
sialidase

MEDICAL DESCRIPTORS:

antibody specificity; article; cancer cell culture; controlled study;  
human; human cell; immunoprecipitation; metastasis--complication--co;  
metastasis...

10/K/36 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2006 Elsevier Science B.V. All rts. reserv.

06197435 EMBASE No: 1995234936  
**Access to peptide regions of a surface mucin (MUC1) is reduced by sialic acids**  
Ho J.J.L.; Cheng S.; Kim Y.S.  
Gastrointestinal Research Laboratory, Veterans Affairs Medical Center, San  
Francisco, CA 94121 United States  
Biochemical and Biophysical Research Communications ( BIOCHEM. BIOPHYS.  
RES. COMMUN. ) (United States) 1995, 210/3 (866-873)  
CODEN: BBRCA ISSN: 0006-291X  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

**Access to peptide regions of a surface mucin (MUC1) is reduced by sialic acids**

...glycoproteins are present on the surfaces of tumor cells. Knowledge of which parts of the mucin molecule are accessible targets for cells of the immune system is important in the development...

...specific for the tripeptide (DTR) in the 20 amino acid tandem repeat of MUC1, and SM - 3 (PDTRP) were greatly enhanced by pre-treating cells with an inhibitor of O-glycosylation, benzyl...

...with an inhibitor of carbohydrate processing, monensin, also greatly

enhanced the reactivities of HMFG-2, SM - 3 and HMFG-1 (PDTR). Thus, sialic acids on termini of neighboring oligosaccharides significantly limit access to the peptide region recognized by antibodies HMFG-1/2 and SM - 3

DRUG DESCRIPTORS:

\* mucin --endogenous compound--ec; \*sialic acid derivative; \*  
sialoglycoprotein  
antibody ; cell surface protein--endogenous compound--ec; galactosamine;  
glycoprotein--endogenous compound--ec; monensin; sialidase

10/K/37 (Item 4 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier Science B.V. All rts. reserv.

05309794 EMBASE No: 1993077879

**Multiple forms of intracellular and secreted mucins in a pancreatic cancer cell line**

Ho J.J.L.; Bi N.; Siddiki B.; Chung Y.-S.; Yuan M.; Kim Y.S.  
GI Research Laboratory, Veterans Affairs Medical Center, 4150 Clement  
Street, San Francisco, CA 94121 United States  
Cancer Research ( CANCER RES. ) (United States) 1993, 53/4 (884-890)  
CODEN: CNREA ISSN: 0008-5472  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

...of the structures of mucins may assist in the development of new therapeutic approaches. Monoclonal antibody Ea6, developed against mucins purified from xenografts of the pancreatic cancer cell line SW1990, was used to identify a new type of pancreatic cancer mucin . The following characteristics suggest that Ea6 antibody reacts with the core structure of O-linked oligosaccharides, the Tn antigen (N- acetylgalactosamine-serine ...

...buoyant densities (1.36 versus 1.44 g/ml) than mucins identified by another monoclonal antibody directed against SW1990 mucins, SPan-1, and were less acidic. High density and molecular mass...

...bond reduction. After partial deglycosylation secreted SPan-1 antigens reacted with MUC1 peptide specific antibodies, SM - 3 and HMFG-2, as well as polyclonal antisera directed against deglycosylated xenograft mucins. However, Ea6...

...prior treatment. No Ea6 reactivity was detected with this fraction. These results suggest that Ea6 antibody identifies a new population of mucins that is distinct from SPan-1 mucins.

DRUG DESCRIPTORS:

\* mucin --endogenous compound--ec

MEDICAL DESCRIPTORS:

antibody specificity; article; carcinogenicity; cell density; cell secretion; cell size; cell subpopulation; controlled study; human; human...

10/K/38 (Item 5 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier Science B.V. All rts. reserv.

05038967 EMBASE No: 1992179183

**Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice**

Peat N.; Gendler S.J.; Lalani E.-N.; Duhig T.; Taylor-Papadimitriou J.  
Imperial Cancer Research Fund, P. O. Box 123, Lincoln's Inn Flds., London  
WC2A 3PX United Kingdom  
Cancer Research ( CANCER RES. ) (United States) 1992, 52/7 (1954-1960)  
CODEN: CNREA ISSN: 0008-5472  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

**Tissue-specific expression of a human polymorphic epithelial mucin  
(MUC1) in transgenic mice**

The human MUC1 gene codes for the core protein of a mucin which is expressed by glandular epithelia and the carcinomas which develop from these tissues. The...

...glycosylated in cancers, and some antibodies show specificity in their reactions with the cancer-associated mucin, which also contains epitopes recognized by T-cells from breast and pancreatic cancer patients. For evaluating the potential use of mucin - reactive antibodies and mucin -based immunogens in cancer patients, a mouse model, expressing the MUC1 gene product PEM (polymorphic epithelial mucin) as a self antigen, would be extremely useful. To this end, we have developed transgenic...

...gene, which was very similar to the profile of expression seen in human tissues. The antibody SM - 3 is directed to a core protein epitope, which is selectively exposed in breast cancers and...

...more restricted distribution on normal human tissues. It was established that the distribution of the SM - 3 epitope of PEM in the tissues of the transgenic mice is similar to that seen...

DRUG DESCRIPTORS:

\*gene product; \* mucin

10/K/39 (Item 6 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2006 Elsevier Science B.V. All rts. reserv.

04895735 EMBASE No: 1992035950

**Purification and characterization of a membrane-bound and a secreted  
mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lesup a  
epitope on distinct core proteins**

Baekstrom D.; Hansson G.C.; Nilsson O.; Johansson C.; Gendler S.J.;  
Lindholm L.

Department of Medical Biochem., University of Goteborg, Box 33031, S-400  
33 Goteborg Sweden

Journal of Biological Chemistry ( J. BIOL. CHEM. ) (United States) 1991  
, 266/32 (21537-21547)

CODEN: JBCHA ISSN: 0021-9258

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

**Purification and characterization of a membrane-bound and a secreted  
mucin -type glycoprotein carrying the carcinoma-associated sialyl-Lesup a  
epitope on distinct core proteins**

Two mucin -type glycoproteins detected by the monoclonal antibody C50,  
which reacts with the carcinoma-associated sialyl-Lewis a and  
sialyl-lactotetraose epitopes, were...

...glycoproteins were purified from xenograft extracts and spent culture



medium using perchloric acid precipitation, monoclonal antibody affinity purification, ion exchange chromatography, and gel filtration. Both glycoproteins were unaffected by reduction and...

...of the intact glycoproteins showed that both H-CanAg and L-CanAg expressed the monoclonal antibody -defined, sialic acid-containing carbohydrate epitopes CA203 and CA242 as well as the Lewis a...

...terminal part of the MUC1 gene product, core protein of the carcinoma-associated polymorphic epithelial mucin (PEM) and DU-PAN-2, reacted with H-CanAg. After deglycosylation with trifluoromethanesulfonic acid, H-CanAg but not L-CanAg was recognized by the monoclonal antibodies SM - 3 and HMFG-2, directed to the tandem repeat of the PEM apoprotein. However, these antibodies...

#### DRUG DESCRIPTORS:

\*epitope; \*glycoprotein--endogenous compound--ec; \* mucin --endogenous compound--ec; \*sialic acid--endogenous compound--ec

10/K/40 (Item 7 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier Science B.V. All rts. reserv.

03989086 EMBASE No: 1989158082

**A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas**

Girling A.; Bartkova J.; Burchell J.; Gendler S.; Gillett C.;  
Taylor-Paradimitriou J.  
Imperial Cancer Research Fund Clinical Oncology Unit, Guy's Hospital,  
London SE1 9RT United Kingdom  
International Journal of Cancer ( INT. J. CANCER ) (United States) 1989  
, 43/6 (1072-1076)  
CODEN: IJCNA ISSN: 0020-7136  
DOCUMENT TYPE: Journal  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

**A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM - 3 is selectively exposed in a range of primary carcinomas**

The monoclonal antibody (MAb) SM - 3 , which was raised to chemically deglycosylated milk mucin , reacts with an epitope present on the core protein of this mucin which we have referred to as PEM (polymorphic epithelial mucin ). Although this mucin is abundantly expressed by both the lactating breast and breast carcinomas, the antibody SM - 3 shows very little or no reactivity on the former but does react with 92% of breast carcinomas. Furthermore, SM - 3 stains primary carcinomas of the lung, colon and ovary, but on the corresponding normal tissue...

...level or not at all. These results indicate that an epitope masked in the normal mucin is exposed in the mucin produced by tumour cells, perhaps due to aberrant glycosylation. An extensive immunohistochemical study of other normal tissues reveals that the majority show only weak focal staining with SM - 3 or none at all, the distal tubules and collecting ducts of the kidney, and sebaceous...

#### DRUG DESCRIPTORS:

\*monoclonal antibody ; \* mucin

10/K/41 (Item 8 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2006 Elsevier Science B.V. All rts. reserv.

03942790 EMBASE No: 1989111783

**Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2**

Stacker S.A.; Tjandra J.J.; Xing P.-X.; Walker I.D.; Thompson C.H.;  
McKenzie I.F.C.

Research Center for Cancer and Transplantation, Department of Pathology,  
University of Melbourne, Parkville, Vic. 3052 Australia

British Journal of Cancer ( BR. J. CANCER ) (United Kingdom) 1989, 59/4  
(544-553)

CODEN: BJCAA ISSN: 0007-0920

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

**Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2**

...from the sera, ascites and breast carcinoma tissue of patients with breast cancer using monoclonal antibody 3E1.2. The 3E1.2 defined antigen, termed mammary serum antigen (MSA) was obtained by...

...acetyl glucosamine as indicated by its binding to wheat-germ agglutinin. The epitope defined by antibody 3E1.2 is sensitive to treatment by sodium periodate and neuraminidase, implying that both carbohydrate and sialic acid are required for binding of antibody 3E1.2. Sandwich immunoassays demonstrated that MSAs + molecules are likely to express repeated 3E1.2  
...

...glycoprotein. It is suggested that MSA has the same core protein as is recognised by antibody DF3 which has been used to clone the same cDNA as was cloned with antibodies HMFG-1, HMFG-2 and SM - 3 . However, the epitope detected by the 3E1.2 antibody is either absent or weakly expressed on human milk, human milk-fat globule membrane (HMFGM) or deglycosylated HMFGM - all of which react strongly with various anti-HMFG antibodies. The antibody 3E1.2 thus recognises a unique epitope of the high molecular weight glycoproteins of human...

DRUG DESCRIPTORS:

milk; monoclonal antibody

10/K/42 (Item 9 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2006 Elsevier Science B.V. All rts. reserv.

03467885 EMBASE No: 1987220466

**Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin**

Burchell J.; Gendler S.; Taylor-Papadimitriou J.; Girling A.; Lewis A.;  
Millis R.; Lampert D.

Imperial Cancer Research Fund, London WC2A 3PX United Kingdom

Cancer Research ( CANCER RES. ) (United States) 1987, 47/20 (5476-5482)

CODEN: CNREA ISSN: 0008-5472

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH

...of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin

A mucin molecule, which has a molecular weight of greater than 400,000 and which carries tumor...

...by affinity chromatography followed by passage through a size exclusion column. While treatment of the mucin with hydrogen fluoride for 1 h at 4degreeC removed the peripheral oligosaccharides, treatment with HF...

...a dominant polypeptide of about 68,000. This appears to be the size of the mucin core protein. Monoclonal antibodies have been developed that react with the stripped and partially stripped molecule but not with the intact mucin. From the initial screening on histological sections one of these antibodies, SM - 3, reacts with 91% of breast carcinomas but shows little or no reactivity on benign mammary tumors, normal resting, pregnant, or lactating breast. It appears that this monoclonal antibody is reacting with an epitope that is usually masked by oligosaccharide moieties in normal cells...

DRUG DESCRIPTORS:

\*tumor antigen; \*monoclonal antibody ; \* mucin ; \*tumor marker

10/K/43 (Item 1 from file: 434)

DIALOG(R)File 434:SciSearch(R) Cited Ref Sci

(c) 2006 The Thomson Corp. All rts. reserv.

09547976 Genuine Article#: AA845 No. References: 21

**Title: A CORE PROTEIN EPITOPE OF THE POLYMORPHIC EPITHELIAL MUCIN DETECTED BY THE MONOCLONAL-ANTIBODY SM-3 IS SELECTIVELY EXPOSED IN A RANGE OF PRIMARY CARCINOMAS**

Author(s): GIRLING A; BARTKOVA J; BURCHELL J; GENDLER S; GILLETT C; TAYLORPAPADIMITRIOU J

Corporate Source: GUYS HOSP,IMPERIAL CANC RES FUND,SOCIAL MED UNIT/LONDON SE1 9RT//ENGLAND/; IMPERIAL CANC RES FUND/LONDON WC2A 3PX//ENGLAND/; RES INST CLIN & EXPTL ONCOL/CS-65601 BRNO//CZECHOSLOVAKIA/

Journal: INTERNATIONAL JOURNAL OF CANCER, 1989, V43, N6, P1072-1076

Language: ENGLISH Document Type: ARTICLE

**Title: A CORE PROTEIN EPITOPE OF THE POLYMORPHIC EPITHELIAL MUCIN DETECTED BY THE MONOCLONAL- ANTIBODY SM - 3 IS SELECTIVELY EXPOSED IN A RANGE OF PRIMARY CARCINOMAS**

10/K/44 (Item 1 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

(c) 2006 The Thomson Corp. All rts. reserv.

04197721 Genuine Article#: RN654 No. References: 43

**Title: ASSOCIATION OF SIALYL-LEWIS(A) AND SIALYL-LEWIS(X) WITH MUC-1 APOMUCIN IN A PANCREATIC-CANCER CELL-LINE**

Author(s): HO JJJ; SIDDIKI B; KIM YS

Corporate Source: UNIV CALIF SAN FRANCISCO,VET ADM MED CTR,4150 CLEMENT ST 151M2/SAN FRANCISCO//CA/94121; UNIV CALIF SAN FRANCISCO,VET AFFAIRS MED CTR,GASTROINTESTINAL RES LAB 151M2/SAN FRANCISCO//CA/94143; UNIV CALIF SAN FRANCISCO,DEPT MED/SAN FRANCISCO//CA/94143

Journal: CANCER RESEARCH, 1995, V55, N16 (AUG 15), P3659-3663

ISSN: 0008-5472

Language: ENGLISH Document Type: ARTICLE (Abstract Available)

...Abstract: by neuraminidase greatly enhanced binding of two other MUC1 peptide specific antibodies, HMFG-2 and SM - 3. After removal of sialic acids, most of the mucins rich in sialyl-Lewis(a) and...

...Identifiers--POLYMORPHIC EPITHELIAL MUCIN ; COLON-CARCINOMA CELLS;  
MONOCLONAL- ANTIBODY ; ADENOCARCINOMA RECOGNIZE; CORE PROTEINS;  
T-CELLS; EXPRESSION; ANTIGEN; BREAST; EPITOPE

10/K/45 (Item 2 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

(c) 2006 The Thomson Corp. All rts. reserv.

04084050 Genuine Article#: RA221 No. References: 36

**Title: ACCESS TO PEPTIDE REGIONS OF A SURFACE MUCIN (MUC1) IS REDUCED BY SIALIC ACIDS**

Author(s): HO JJL; CHENG S; KIM YS

Corporate Source: VET AFFAIRS MED CTR,GASTROINTESTINAL RES LAB 151M2/SAN  
FRANCISCO//CA/94121; UNIV CALIF SAN FRANCISCO,DEPT MED/SAN  
FRANCISCO//CA/00000

Journal: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, V210,  
N3 (MAY 25), P866-873

ISSN: 0006-291X

Language: ENGLISH Document Type: ARTICLE (Abstract Available)

**Title: ACCESS TO PEPTIDE REGIONS OF A SURFACE MUCIN (MUC1) IS REDUCED BY SIALIC ACIDS**

...Abstract: glycoproteins are present on the surfaces of tumor cells.  
Knowledge of which parts of the mucin molecule are accessible targets  
for cells of the immune system is important in the development...

...specific for the tripeptide (DTR) in the 20 amino acid tandem repeat of  
MUC1, and SM - 3 (PDTRP) were greatly enhanced by pre-treating cells  
with an inhibitor of O-glycosylation, benzyl...

...with an inhibitor of carbohydrate processing, monensin, also greatly  
enhanced the reactivities of HMFG-2, SM - 3 and HMFG-1 (PDTR). Thus,  
sialic acids on termini of neighboring oligosaccharides significantly  
limit access to the peptide region recognized by antibodies HMFG-1/2  
and SM - 3 . (C) Academic Press, Inc.

...Identifiers--POLYMORPHIC EPITHELIAL MUCIN ; MONOCLONAL- ANTIBODY ;  
ADENOCARCINOMA RECOGNIZE; T-CELLS; CORE; ANTIGEN; EPISIALIN; ADHESION;  
EPITOPE; BREAST

10/K/46 (Item 3 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

(c) 2006 The Thomson Corp. All rts. reserv.

02233281 Genuine Article#: KL963 No. References: 41

**Title: MULTIPLE FORMS OF INTRACELLULAR AND SECRETED MUCINS IN A PANCREATIC-CANCER CELL-LINE**

Author(s): HO JJL; BI N; SIDDIKI B; CHUNG YS; YUAN M; KIM YS

Corporate Source: VET AFFAIRS MED CTR,GI RES LAB 151M2,4150 CLEMENT ST/SAN  
FRANCISCO//CA/94121; UNIV CALIF SAN FRANCISCO,DEPT 22J/SAN  
FRANCISCO//CA/94121; OSAKA CITY UNIV,SCH MED,DEPT SURG 1/OSAKA  
545//JAPAN/

Journal: CANCER RESEARCH, 1993, V53, N4 (FEB 15), P884-890

ISSN: 0008-5472

Language: ENGLISH Document Type: ARTICLE (Abstract Available)

...Abstract: of the structures of mucins may assist in the development of  
new therapeutic approaches. Monoclonal antibody Ea6, developed  
against mucins purified from xenografts of the pancreatic cancer cell  
line SW1990, was used to identify a new type of pancreatic cancer

mucin . The following characteristics suggest that Ea6 antibody reacts with the core structure of O-linked oligosaccharides, the Tn antigen (N-acetylgalactosamine-serine...

- ...buoyant densities (1.36 versus 1.44 g/ml) than mucins identified by another monoclonal antibody directed against SW1990 mucins, SPan-1, and were less acidic. High density and molecular mass...
- ...bond reduction. After partial deglycosylation secreted SPan-1 antigens reacted with MUC1 peptide specific antibodies, SM - 3 and HMFG-2, as well as polyclonal antisera directed against deglycosylated xenograft mucins. However, Ea6...
- ...prior treatment. No Ea6 reactivity was detected with this fraction. These results suggest that Ea6 antibody identifies a new population of mucins that is distinct from SPan-1 mucins.
- ...Identifiers--MURINE MONOCLONAL-ANTIBODIES; ADENOCARCINOMA CELLS; SUBMAXILLARY MUCIN ; MOLECULAR-CLONING; GLYCOPROTEIN; PURIFICATION; ANTIGEN; GENE; OLIGOSACCHARIDES; SIALOMUCIN
- Research Fronts: 91-2924 001 (HUMAN POLYMORPHIC EPITHELIAL MUCIN GENE; SERUM MARKERS IN BREAST-CANCER; ANTIGEN EXPRESSION)
- 91-4134 001 (LEWIS BLOOD-GROUP ANTIGENS; ORAL SQUAMOUS-CELL CARCINOMAS; PANCREAS CANCER)
- 91-4226 001 (I-131 B72.3 MONOCLONAL- ANTIBODY ; SERUM TUMOR-ASSOCIATED GLYCOPROTEIN-72; PANCREATIC ADENOCARCINOMA; INVITRO CLINICAL-APPLICATIONS)

10/K/47 (Item 4 from file: 34)  
 DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
 (c) 2006 The Thomson Corp. All rts. reserv.

01611489 Genuine Article#: HL505 No. References: 38  
**Title: TISSUE-SPECIFIC EXPRESSION OF A HUMAN POLYMORPHIC EPITHELIAL MUCIN (MUC1) IN TRANSGENIC MICE**  
 Author(s): PEAT N; GENDLER SJ; LALANI EN; DUHIG T; TAYLORPAPADIMITRIOU J  
 Corporate Source: IMPERIAL CANC RES FUND,POB 123,LINCOLNS INN FIELDS/LONDON WC2A 3PX//ENGLAND//; IMPERIAL CANC RES FUND,POB 123,LINCOLNS INN FIELDS/LONDON WC2A 3PX//ENGLAND/  
 Journal: CANCER RESEARCH, 1992, V52, N7 (APR 1), P1954-1960  
 Language: ENGLISH Document Type: ARTICLE (Abstract Available)

**Title: TISSUE-SPECIFIC EXPRESSION OF A HUMAN POLYMORPHIC EPITHELIAL MUCIN (MUC1) IN TRANSGENIC MICE**  
 Abstract: The human MUC1 gene codes for the core protein of a mucin which is expressed by glandular epithelia and the carcinomas which develop from these tissues. The...

- ...glycosylated in cancers, and some antibodies show specificity in their reactions with the cancer-associated mucin , which also contains epitopes recognized by T-cells from breast and pancreatic cancer patients. For evaluating the potential use of mucin -reactive antibodies and mucin -based immunogens in cancer patients, a mouse model, expressing the MUC1 gene product PEM (polymorphic epithelial mucin ) as a self antigen, would be extremely useful. To this end, we have developed transgenic...
- ...gene, which was very similar to the profile of expression seen in human tissues. The antibody SM - 3 is directed to a core protein epitope, which is selectively exposed in breast cancers and...

...more restricted distribution on normal human tissues. It was established that the distribution of the SM - 3 epitope of PEM in the tissues of the transgenic mice is similar to that seen...

Research Fronts: 90-3502 004 (PROTEIN CORE OF HUMAN POLYMORPHIC EPITHELIAL MUCIN ; MARKERS FOR BREAST-CANCER; OVARIAN CARCINOMA-ASSOCIATED SEBACEOUS GLAND ANTIGEN)  
90-1469 001 (DIFFERENTIAL EXPRESSION...

10/K/48 (Item 5 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2006 The Thomson Corp. All rts. reserv.

01480063 Genuine Article#: HC030 No. References: 35  
Title: CHARACTERIZATION OF EPITHELIAL PHENOTYPES IN MORTAL AND IMMORTAL HUMAN BREAST CELLS

Author(s): PAINE TM; SOULE HD; PAULEY RJ; DAWSON PJ  
Corporate Source: MICHIGAN CANC FDN,110 E WARREN AVE/DETROIT//MI/48201;  
MICHIGAN CANC FDN,110 E WARREN AVE/DETROIT//MI/48201; UNIV S FLORIDA,MED LAB/TAMPA//FL/33612; UNIV S FLORIDA,DEPT PATHOL/TAMPA//FL/33612

Journal: INTERNATIONAL JOURNAL OF CANCER, 1992, V50, N3 (FEB 1), P463-473  
Language: ENGLISH Document Type: ARTICLE (Abstract Available)

...Abstract: 2-dimensional gel Western blots and immunoperoxidase staining with antibodies to cytokeratins and polymorphic epithelial mucin . MCF-10M and MCF-12M retain the cytokeratin profile of the luminal cell (7, 8...

...the morphologically mixed, less-selected population of MCF-10-2. Epitopes on the polymorphic epithelial mucin , recognized by antibodies HMFG 1, HMFG 2 and SM - 3 , were detected in the mortal cultures and in the immortal lines, indicating the occurrence of both normal and abnormal mucin processing. MCF-10, MCF-10-2 and MCF-12 cells do not form tumors in...

...Identifiers--MONOCLONAL- ANTIBODY ; KERATIN EXPRESSION; DNA; DIFFERENTIATION; MARKERS; GROWTH; HMFG-2; MCF-10; MUCIN; LINE  
Research Fronts: 90-3502 002 (PROTEIN CORE OF HUMAN POLYMORPHIC EPITHELIAL MUCIN ; MARKERS FOR BREAST-CANCER; OVARIAN CARCINOMA-ASSOCIATED SEBACEOUS GLAND ANTIGEN)  
90-4331 002 (KERATIN EXPRESSION...

10/K/49 (Item 6 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2006 The Thomson Corp. All rts. reserv.

01458157 Genuine Article#: HA276 No. References: 0  
Title: EXPRESSION OF THE CORE PROTEIN OF POLYMORPHIC EPITHELIAL MUCIN AS DETECTED BY SM-3 ANTIBODY IN PULMONARY ADENOCARCINOMA AND PLEURAL MALIGNANT MESOTHELIOMA

Author(s): SOOHOO WEJ; ORDONEZ NG  
Corporate Source: UNIV TEXAS,MD ANDERSON CANC CTR/HOUSTON//TX/77025  
Journal: LABORATORY INVESTIGATION, 1992, V66, N1 (JAN), P116  
Language: ENGLISH Document Type: MEETING ABSTRACT

Title: EXPRESSION OF THE CORE PROTEIN OF POLYMORPHIC EPITHELIAL MUCIN AS DETECTED BY SM - 3 ANTIBODY IN PULMONARY ADENOCARCINOMA AND PLEURAL MALIGNANT MESOTHELIOMA

10/K/50 (Item 7 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

(c) 2006 The Thomson Corp. All rts. reserv.

01328314 Genuine Article#: GP804 No. References: 44

**Title: PURIFICATION AND CHARACTERIZATION OF A MEMBRANE-BOUND AND A SECRETED MUCIN-TYPE GLYCOPROTEIN CARRYING THE CARCINOMA-ASSOCIATED SIALYL-LE(A) EPI TOPE ON DISTINCT CORE PROTEINS**

Author(s): BAECKSTROM D; HANSSON GC; NILSSON O; JOHANSSON C; GENDLER SJ; LINDHOLM L

Corporate Source: GOTHENBURG UNIV,DEPT MED BIOCHEM,BOX 33031/S-40033 GOTHENBURG//SWEDEN/; PHARMACIA CANAG/S-40242 GOTHENBURG//SWEDEN/; DEPT MED MICROBIOL & IMMUNOL/S-41346 GOTHENBURG//SWEDEN/; IMPERIAL CANC RES FUND/LONDON WC2A 3PX//ENGLAND/

Journal: JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, V266, N32, P21537-21547

Language: ENGLISH Document Type: ARTICLE (Abstract Available)

**Title: PURIFICATION AND CHARACTERIZATION OF A MEMBRANE-BOUND AND A SECRETED MUCIN -TYPE GLYCOPROTEIN CARRYING THE CARCINOMA-ASSOCIATED SIALYL-LE(A) EPI TOPE ON DISTINCT CORE PROTEINS**

Abstract: Two mucin -type glycoproteins detected by the monoclonal antibody C50, which reacts with the carcinoma-associated sialyl-Lewis a and sialyl-lactotetraose epitopes, were...

...glycoproteins were purified from xenograft extracts and spent culture medium using perchloric acid precipitation, monoclonal antibody affinity purification, ion exchange chromatography, and gel filtration. Both glycoproteins were unaffected by reduction and...

...of the intact glycoproteins showed that both H-CanAg and L-CanAg expressed the monoclonal antibody -defined, sialic acid-containing carbohydrate epitopes CA203 and CA242 as well as the Lewis a...

...terminal part of the MUC1 gene product, core protein of the carcinoma-associated Polymorphic epithelial mucin (PEM) and DU-PAN-2, reacted with H-CanAg. After deglycosylation with trifluoromethanesulfonic acid, H-CanAg but not L-CanAg was recognized by the monoclonal antibodies SM - 3 and HMFG-2, directed to the tandem repeat of the PEM apoprotein. However, these antibodies...

...Identifiers--POLYMORPHIC EPITHELIAL MUCIN ; N-FUCOPENTAPOSE-II; MONOCLONAL-ANTIBODIES; HUMAN-MILK; CANCER; ANTIGEN; GANGLIOSIDES; EXPRESSION; ADENOCARCINOMA; BIOSYNTHESIS

...Research Fronts: HUMAN MYELOID CELLS; CARBOHYDRATE ANTIGENS; DIFFERENT GRADES OF TRANSFORMATION)

89-1356 001 (CARCINOEMBRYONIC ANTIGEN; MONOCLONAL- ANTIBODY B72.3; TUMOR-ASSOCIATED GLYCOPROTEIN (TAG-72) EXPRESSION; HUMAN-COLON CARCINOMA; MALIGNANT PANCREATIC LESIONS)

89...

?

Set	Items	Description
S1	27	(POLYMORPHIC (N) EPITHELIAL (N) MUCIN) AND CLONE
S2	43	(EPITHELIAL (W) MUCIN) AND CLONE
S3	0	S1 AND SM-3
S4	0	S2 AND SM-3
S5	1	(S1 AND (SM (W) 3))
S6	1	S2 AND (SM (W) 3)

S7 1765000 (SM (W) 3) AND MONOCLONAL OR ANTIBODY  
 S8 1765000 ((SM (W) 3) AND MONOCLONAL OR ANTIBODY)  
 S9 88 ((SM (W) 3) AND ANTIBODY)  
 S10 50 S9 AND MUCIN  
 S11 305313 (S10 AND GENE OR CLONE)  
 S12 4 (S10 AND CLONE)  
 S13 7 (S10 AND DNA)  
 ?

TYPE S12/MEDIUM,K/1-4

12/K/1 (Item 1 from file: 155)  
 DIALOG(R)File 155:MEDLINE(R)  
 (c) format only 2006 Dialog. All rts. reserv.

08050539 PMID: 2469454

**Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2.**

Stacker S A; Tjandra J J; Xing P X; Walker I D; Thompson C H; McKenzie I F

Department of Pathology, University of Melbourne, Victoria, Australia.  
 British journal of cancer (ENGLAND) Apr 1989, 59 (4) p544-53, ISSN  
 0007-0920--Print Journal Code: 0370635  
 Publishing Model Print  
 Document type: Journal Article  
 Languages: ENGLISH  
 Main Citation Owner: NLM  
 Record type: MEDLINE; Completed

**Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2.**

... from the sera, ascites and breast carcinoma tissue of patients with breast cancer using monoclonal antibody 3E1.2. The 3E1.2 defined antigen, termed mammary serum antigen (MSA) was obtained by...

...acetyl glucosamine as indicated by its binding to wheat-germ agglutinin. The epitope defined by antibody 3E1.2 is sensitive to treatment by sodium periodate and neuraminidase, implying that both carbohydrate and sialic acid are required for binding of antibody 3E1.2. Sandwich immunoassays demonstrated that MSA+ molecules are likely to express repeated 3E1.2...

... glycoprotein. It is suggested that MSA has the same core protein as is recognised by antibody DF3 which has been used to clone the same cDNA as was cloned with antibodies HMFG-1, HMFG-2 and SM - 3. However, the epitope detected by the 3E1.2 antibody is either absent or weakly expressed on human milk, human milk-fat globule membrane (HMFGM) or deglycosylated HMFGM--all of which react strongly with various anti-HMFG antibodies. The antibody 3E1.2 thus recognises a unique epitope of the high molecular weight glycoproteins of human...

12/K/2 (Item 1 from file: 159)  
 DIALOG(R)File 159:Cancerlit  
 (c) format only 2002 Dialog. All rts. reserv.

01728393 89228880 PMID: 2469454

**Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2.**

Stacker S A; Tjandra J J; Xing P X; Walker I D; Thompson C H; McKenzie I F



Department of Pathology, University of Melbourne, Victoria, Australia.

Br J Cancer (ENGLAND) Apr 1989, 59 (4) p544-53, ISSN 0007-0920

Journal Code: 0370635

Document Type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2.**

... from the sera, ascites and breast carcinoma tissue of patients with breast cancer using monoclonal antibody 3E1.2. The 3E1.2 defined antigen, termed mammary serum antigen (MSA) was obtained by...

...acetyl glucosamine as indicated by its binding to wheat-germ agglutinin. The epitope defined by antibody 3E1.2 is sensitive to treatment by sodium periodate and neuraminidase, implying that both carbohydrate and sialic acid are required for binding of antibody 3E1.2. Sandwich immunoassays demonstrated that MSA+ molecules are likely to express repeated 3E1.2...

... glycoprotein. It is suggested that MSA has the same core protein as is recognised by antibody DF3 which has been used to clone the same cDNA as was cloned with antibodies HMFG-1, HMFG-2 and SM - 3. However, the epitope detected by the 3E1.2 antibody is either absent or weakly expressed on human milk, human milk-fat globule membrane (HMFGM) or deglycosylated HMFGM--all of which react strongly with various anti-HMFG antibodies. The antibody 3E1.2 thus recognises a unique epitope of the high molecular weight glycoproteins of human...

12/K/3 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0006702079 BIOSIS NO.: 198988017194

**PURIFICATION AND BIOCHEMICAL CHARACTERIZATION OF A NOVEL BREAST CARCINOMA ASSOCIATED MUCIN-LIKE GLYCOPROTEIN DEFINED BY ANTIBODY 3E1.2**

AUTHOR: STACKER S A (Reprint); TJANDRA J J; XING P-X; WALKER I D; THOMPSON C H; MCKENZIE I F C

AUTHOR ADDRESS: RES CENTRE CANCER AND TRANSPLANTATION, DEP PATHOLOGY, UNIV MELBOURNE, PARKVILLE, 3052 VICTORIA, AUSTRALIA\*\*AUSTRALIA

JOURNAL: British Journal of Cancer 59 (4): p545-553 1989

ISSN: 0007-0920

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

**PURIFICATION AND BIOCHEMICAL CHARACTERIZATION OF A NOVEL BREAST CARCINOMA ASSOCIATED MUCIN-LIKE GLYCOPROTEIN DEFINED BY ANTIBODY 3E1.2**

...ABSTRACT: from the sera, ascites and breast carcinoma tissue of patients with breast cancer using monoclonal antibody 3E1.2. The 3E1.2 defined antigen, termed mammary serum antigen (MSA) was obtained by...

...acetyl glucosamine as indicated by its binding to wheat-germ agglutinin. The epitope defined by antibody 3E1.2 is sensitive to treatment by sodium periodate and neuraminidase, implying that both carbohydrate and sialic acid are required for binding of antibody 3E1.2. Sandwich immunoassays demonstrated that MSA+ molecules are likely to express repeated 3E1.2...

...glycoprotein. It is suggested that MSA has the same core protein as is recognised by antibody DF3 which has been used to clone the same cDNA as was cloned with antibodies HMEG-1, HMFG-2 and SM - 3 . However, the epitope detected by the 3E1.2 antibody is either absent or weakly expressed on human milk, human milk-fat globule membrane (HMFGM) or deglycosylated HMFGM- all of which react strongly with various anti-HMFG antibodies. The antibody 3E1.2 thus recognises a unique epitope of the high molecular weight glycoproteins of human...

DESCRIPTORS: HUMAN MAMMARY SERUM ANTIGEN TUMOR-ASSOCIATED ANTIGEN ASCITES  
BREAST CANCER TISSUE MURINE MONOCLONAL ANTIBODY SANDWICH ELISA

12/K/4 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2006 Elsevier Science B.V. All rts. reserv.

03942790 EMBASE No: 1989111783

**Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2**

Stacker S.A.; Tjandra J.J.; Xing P.-X.; Walker I.D.; Thompson C.H.;  
McKenzie I.F.C.

Research Center for Cancer and Transplantation, Department of Pathology,  
University of Melbourne, Parkville, Vic. 3052 Australia  
British Journal of Cancer ( BR. J. CANCER ) (United Kingdom) 1989, 59/4  
(544-553)

CODEN: BJCAA ISSN: 0007-0920

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

**Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2**

...from the sera, ascites and breast carcinoma tissue of patients with breast cancer using monoclonal antibody 3E1.2. The 3E1.2 defined antigen, termed mammary serum antigen (MSA) was obtained by...

...acetyl glucosamine as indicated by its binding to wheat-germ agglutinin. The epitope defined by antibody 3E1.2 is sensitive to treatment by sodium periodate and neuraminidase, implying that both carbohydrate and sialic acid are required for binding of antibody 3E1.2. Sandwich immunoassays demonstrated that MSAsup + molecules are likely to express repeated 3E1.2 ...

...glycoprotein. It is suggested that MSA has the same core protein as is recognised by antibody DF3 which has been used to clone the same cDNA as was cloned with antibodies HMFG-1, HMFG-2 and SM - 3 . However, the epitope detected by the 3E1.2 antibody is either absent or weakly expressed on human milk, human milk-fat globule membrane (HMFGM) or deglycosylated HMFGM - all of which react strongly with various anti-HMFG antibodies. The antibody 3E1.2 thus recognises a unique epitope of the high molecular weight glycoproteins of human...

DRUG DESCRIPTORS:

milk; monoclonal antibody

?

Set	Items	Description
S1	27	(POLYMORPHIC (N) EPITHELIAL (N) MUCIN) AND CLONE
S2	43	(EPITHELIAL (W) MUCIN) AND CLONE

```

S3      0      S1 AND SM-3
S4      0      S2 AND SM-3
S5      1      (S1 AND (SM (W) 3))
S6      1      S2 AND (SM (W) 3)
S7      1765000 (SM (W) 3) AND MONOCLONAL OR ANTIBODY
S8      1765000 ((SM (W) 3) AND MONOCLONAL OR ANTIBODY)
S9      88      ((SM (W) 3) AND ANTIBODY)
S10     50      S9 AND MUCIN
S11     305313  (S10 AND GENE OR CLONE)
S12     4       (S10 AND CLONE)
S13     7       (S10 AND DNA)
?
```

TYPE S13/MEDIUM,K/1-7

13/K/1 (Item 1 from file: 155)  
 DIALOG(R)File 155:MEDLINE(R)  
 (c) format only 2006 Dialog. All rts. reserv.

09186073 PMID: 1372533

**Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.**

Peat N; Gendler S J; Lalani N; Duhig T; Taylor-Papadimitriou J  
 Imperial Cancer Research Fund, Lincoln's Inn Fields, London, England.  
 Cancer research (UNITED STATES) Apr 1 1992, 52 (7) p1954-60, ISSN  
 0008-5472--Print Journal Code: 2984705R  
 Publishing Model Print  
 Document type: Journal Article  
 Languages: ENGLISH  
 Main Citation Owner: NLM  
 Record type: MEDLINE; Completed

**Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.**

The human MUC1 gene codes for the core protein of a mucin which is expressed by glandular epithelia and the carcinomas which develop from these tissues. The...

... glycosylated in cancers, and some antibodies show specificity in their reactions with the cancer-associated mucin, which also contains epitopes recognized by T-cells from breast and pancreatic cancer patients. For evaluating the potential use of mucin-reactive antibodies and mucin-based immunogens in cancer patients, a mouse model, expressing the MUC1 gene product PEM (polymorphic epithelial mucin) as a self antigen, would be extremely useful. To this end, we have developed transgenic...

... gene, which was very similar to the profile of expression seen in human tissues. The antibody SM - 3 is directed to a core protein epitope, which is selectively exposed in breast cancers and...

...more restricted distribution on normal human tissues. It was established that the distribution of the SM - 3 epitope of PEM in the tissues of the transgenic mice is similar to that seen...

; Animals; Antibodies; Blotting, Northern; Blotting, Southern; CA-15-3 Antigen; Culture Techniques; DNA --genetics--GE; DNA --isolation and purification--IP; Genomic Library; Humans; Immunohistochemistry; Lactation --physiology--PH; Lymphocytes--physiology--PH; Mammary...

Chemical Name: Antibodies; CA-15-3 Antigen; Membrane Glycoproteins; Mucins; RNA; DNA

13/K/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

08195471 PMID: 2477336

**A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.**

Burchell J; Taylor-Papadimitriou J; Boshell M; Gendler S; Duhig T  
Imperial Cancer Research Fund, London, UK.

International journal of cancer. Journal international du cancer (UNITED STATES) Oct 15 1989, 44 (4) p691-6, ISSN 0020-7136--Print

Journal Code: 0042124

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

**A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.**

The polymorphic epithelial mucin (PEM) appears to be the target molecule for many monoclonal antibodies (MAbs) which react with...

... have precisely mapped the epitopes of 4 MAbs reactive with the tandem repeats including one, SM - 3, which shows enhanced tumour specificity. We report that the core of the SM - 3 epitope corresponds to the continuous amino acid sequence Pro-Asp-Thr-Arg-Pro. We also...

... However, none of these epitopes contain the proline found at the amino end of the SM - 3 determinant. These results are consistent with the idea that, in the cancer-associated mucin, premature termination of the carbohydrate side-chains results in the exposure of the SM - 3 epitope.

Descriptors: \*Antigens, Tumor-Associated, Carbohydrate--genetics--GE; \*DNA --genetics--GE; \*Epitopes--genetics--GE; \*Mucins--genetics--GE; \*Repetitive Sequences, Nucleic Acid; Amino Acid Sequence; Antibodies, Monoclonal--analysis--AN; Antigens, Tumor-Associated, Carbohydrate--immunology--IM; Binding Sites, Antibody --genetics--GE; Binding Sites, Antibody --immunology--IM; Enzyme-Linked Immunosorbent Assay; Epitopes --immunology--IM; Humans; Molecular Sequence Data; Mucins--immunology...

Chemical Name: Antibodies, Monoclonal; Antigens, Tumor-Associated, Carbohydrate; Binding Sites, Antibody; Epitopes; Mucins; DNA

13/K/3 (Item 1 from file: 159)

DIALOG(R) File 159:Cancerlit

(c) format only 2002 Dialog. All rts. reserv.

01924587 92200415 PMID: 1372533

**Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.**

Peat N; Gendler S J; Lalani N; Duhig T; Taylor-Papadimitriou J  
Imperial Cancer Research Fund, Lincoln's Inn Fields, London, England.

Cancer Res (UNITED STATES) Apr 1 1992, 52 (7) p1954-60, ISSN 0008-5472 Journal Code: 2984705R

Document Type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.**

The human MUC1 gene codes for the core protein of a mucin which is expressed by glandular epithelia and the carcinomas which develop from these tissues. The...

... glycosylated in cancers, and some antibodies show specificity in their reactions with the cancer-associated mucin, which also contains epitopes recognized by T-cells from breast and pancreatic cancer patients. For evaluating the potential use of mucin-reactive antibodies and mucin-based immunogens in cancer patients, a mouse model, expressing the MUC1 gene product PEM (polymorphic epithelial mucin) as a self antigen, would be extremely useful. To this end, we have developed transgenic...

... gene, which was very similar to the profile of expression seen in human tissues. The antibody SM - 3 is directed to a core protein epitope, which is selectively exposed in breast cancers and...

...more restricted distribution on normal human tissues. It was established that the distribution of the SM - 3 epitope of PEM in the tissues of the transgenic mice is similar to that seen...

Minor Descriptors: Antibodies; Blotting, Northern; Blotting, Southern; CA-15-3 Antigen; DNA --genetics--GE; DNA --isolation and purification --IP; Genomic Library; Immunohistochemistry; Lactation--physiology--PH; Lymphocytes--physiology--PH; Mammae--physiology...

Chemical Name: Antibodies; CA-15-3 Antigen; Membrane Glycoproteins; Mucins; RNA; DNA

13/K/4 (Item 2 from file: 159)

DIALOG(R)File 159:Cancerlit

(c) format only 2002 Dialog. All rts. reserv.

01781134 PMID: 91668429

**EPITHELIAL MUCIN ANTIBODIES AND THEIR EPITOPES: CORE PROTEIN EPITOPES OF A POLYMORPHIC EPITHELIAL MUCIN (PEM).**

Taylor-Papadimitriou; Burchell; Gendler; Boshell; Duhig  
Imperial Cancer Res. Fund, P.O. Box 123, Lincoln's Inn Fields, London WC2A 3PX, UK

Non-serial 1989, Breast Cancer Immunodiagnosis and Immunotherapy. Ceriani RL, ed. New York, Plenum, p. 81-93, 1989.,

Document Type: MEETING PAPER

Languages: ENGLISH

Main Citation Owner: NOTNLM

Record type: Completed

**EPITHELIAL MUCIN ANTIBODIES AND THEIR EPITOPES: CORE PROTEIN EPITOPES OF A POLYMORPHIC EPITHELIAL MUCIN (PEM).**

Data have been obtained recently from a human mucin that is expressed by several simple epithelial cell types and abundantly by the lactating mammary gland and by many carcinomas. This mucin, called PEM because of the high degree of polymorphism seen at the DNA and protein level, is highly immunogenic, and many antibodies raised against normal and malignant epithelial...

... PEM repeat unit exhibit features that would be expected in the core protein of a mucin. There are five potential O glycosylation sites represented by serines and threonines separated by proline-rich stretches of 3, 5, and 7 AAs. The enhanced tumor specificity of the antibody SM - 3 directed to the deglycosylated PEM indicates that the epitopes to the core protein, which normally are masked, can be exposed in the

cancer-associated mucin (CAM). Thus, at least some of the difference between the normally processed mucin and the mucin expressed in breast cancers may be due to differences in glycosylation patterns. The exposure of core protein epitopes in the cancer mucin could be due to underglycosylation of potential glycosylation sites or to a reduction in the length of the added oligosaccharide side chains. The mapping of the SM - 3 and HMFG-2 epitopes to AAs around a threonine residue in the tandem repeat sequence...

... for shorter oligosaccharide side chains on the CAM is provided by the observation that the SM - 3 epitope, which is only exposed in this form of the mucin, contains extra AAs flanking the HMFG-2 epitope, some of which apparently are masked in...

13/K/5 (Item 3 from file: 159)

DIALOG(R)File 159:Cancerlit

(c) format only 2002 Dialog. All rts. reserv.

01752977 90007760 PMID: 2477336

**A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.**

Burchell J; Taylor-Papadimitriou J; Boshell M; Gendler S; Duhig T

Imperial Cancer Research Fund, London, UK.

Int J Cancer (UNITED STATES) Oct 15 1989, 44 (4) p691-6, ISSN

0020-7136 Journal Code: 0042124

Document Type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.**

The polymorphic epithelial mucin (PEM) appears to be the target molecule for many monoclonal antibodies (MAbs) which react with...

... have precisely mapped the epitopes of 4 MAbs reactive with the tandem repeats including one, SM - 3, which shows enhanced tumour specificity. We report that the core of the SM - 3 epitope corresponds to the continuous amino acid sequence Pro-Asp-Thr-Arg-Pro. We also...

... However, none of these epitopes contain the proline found at the amino end of the SM - 3 determinant. These results are consistent with the idea that, in the cancer-associated mucin, premature termination of the carbohydrate side-chains results in the exposure of the SM - 3 epitope.

Major Descriptors: \*Antigens, Tumor-Associated, Carbohydrate--genetics--GE; \*DNA --genetics--GE; \*Epitopes--genetics--GE; \*Mucins--genetics--GE; \*Repetitive Sequences, Nucleic Acid

Minor Descriptors: Amino Acid Sequence; Antibodies, Monoclonal--analysis--AN; Antigens, Tumor-Associated, Carbohydrate--immunology--IM; Binding Sites, Antibody --genetics--GE; Binding Sites, Antibody --immunology--IM; Enzyme-Linked Immunosorbent Assay; Epitopes--immunology--IM; Molecular Sequence Data; Mucins--immunology--IM...

Chemical Name: Antibodies, Monoclonal; Antigens, Tumor-Associated, Carbohydrate; Binding Sites, Antibody; Epitopes; Mucins; DNA

13/K/6 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier Science B.V. All rts. reserv.

07812092 EMBASE No: 1999301656

**Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes**

Beum P.V.; Singh J.; Burdick M.; Hollingsworth M.A.; Cheng P.-W.  
P.-W. Cheng, Dept. of Biochem./Molecular Biology, University of Nebraska  
Med. Center, 984525 Nebraska Medical Center, Omaha, NE 68198-4525 United  
States

AUTHOR EMAIL: pcheng@unmc.edu

Journal of Biological Chemistry ( J. BIOL. CHEM. ) (United States) 27

AUG 1999, 274/35 (24641-24648)

CODEN: JBCHA ISSN: 0021-9258

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 50

...stable transfection of a human pancreatic adenocarcinoma cell line, Panc1-MUC1, with the cDNA for mucin core 2 GlcNAc-transferase (C2GnT), which creates the core 2 beta-1,6 branch in mucin -type glycans. These cells lack endogenous C2GnT activity but express a recombinant human MUC1 cDNA...

...clones expressing different levels of C2GnT were characterized using monoclonal antibodies CC49, CSLEX-1, and SM - 3 , which recognize tumor-associated epitopes. Increased C2GnT expression led to greatly diminished expression of the...

...transfectants could not bind to selectins. Increased C2GnT expression also led to masking of the SM - 3 peptide epitope, which persisted after the removal of sialic acid, further suggesting greater complexity of...

**DRUG DESCRIPTORS:**

complementary DNA ; mucin ; glycan; monoclonal antibody ; selectin;  
sialic acid; ligand

13/K/7 (Item 1 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

(c) 2006 The Thomson Corp. All rts. reserv.

01480063 Genuine Article#: HC030 No. References: 35

**Title: CHARACTERIZATION OF EPITHELIAL PHENOTYPES IN MORTAL AND IMMORTAL HUMAN BREAST CELLS**

Author(s): PAINE TM; SOULE HD; PAULEY RJ; DAWSON PJ

Corporate Source: MICHIGAN CANC FDN,110 E WARREN AVE/DETROIT//MI/48201;

MICHIGAN CANC FDN,110 E WARREN AVE/DETROIT//MI/48201; UNIV S

FLORIDA,MED LAB/TAMPA//FL/33612; UNIV S FLORIDA,DEPT

PATHOL/TAMPA//FL/33612

Journal: INTERNATIONAL JOURNAL OF CANCER, 1992, V50, N3 (FEB 1), P463-473

Language: ENGLISH Document Type: ARTICLE (Abstract Available)

...Abstract: immortal line after long-term cultivation of MCF-12M mortal cells from reduction mammaplasty tissue. DNA finger-printing demonstrated the independent, human origin and lineage of the MCF-10-2 and...

...2-dimensional gel Western blots and immunoperoxidase staining with antibodies to cytokeratins and polymorphic epithelial mucin . MCF-10M and MCF-12M retain the cytokeratin profile of the luminal cell (7, 8...

...the morphologically mixed, less-selected population of MCF-10-2.  
Epitopes on the polymorphic epithelial mucin , recognized by

antibodies HMFG 1, HMFG 2 and SM - 3 , were detected in the mortal cultures and in the immortal lines, indicating the occurrence of both normal and abnormal mucin processing. MCF-10, MCF-10-2 and MCF-12 cells do not form tumors in...

...Identifiers--MONOCLONAL- ANTIBODY ; KERATIN EXPRESSION; DNA;  
DIFFERENTIATION; MARKERS; GROWTH; HMFG-2; MCF-10; MUCIN; LINE  
Research Fronts: 90-3502 002 (PROTEIN CORE OF HUMAN POLYMORPHIC  
EPITHELIAL MUCIN ; MARKERS FOR BREAST-CANCER; OVARIAN  
CARCINOMA-ASSOCIATED SEBACEOUS GLAND ANTIGEN)  
90-4331 002 (KERATIN EXPRESSION...  
?



 PALM IntranetApplication  
Number  

IDS Flag Clearance for Application 10766020

**IDS**  
Information

Content	Mailroom Date	Entry Number	IDS Review	Last Modified	Reviewer
M844	2005-01-29	11	Y <input checked="" type="checkbox"/>	2006-07-24 13:44:45.0	LBristol
<input type="button" value="Update"/>					

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 6 MAY 11 KOREAPAT updates resume  
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and  
USPATFULL/USPAT2  
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS  
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC  
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and  
and display fields  
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL  
NEWS 13 JUL 11 CHEMSAFE reloaded and enhanced  
NEWS 14 JUL 14 FSTA enhanced with Japanese patents  
NEWS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI  
  
NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:08:55 ON 01 AUG 2006

=> file caplus, bioeng, biotechno, biotechds, esbiobase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 15:09:23 ON 01 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOENG' ENTERED AT 15:09:23 ON 01 AUG 2006  
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHNO' ENTERED AT 15:09:23 ON 01 AUG 2006  
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHDS' ENTERED AT 15:09:23 ON 01 AUG 2006  
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'ESBIOBASE' ENTERED AT 15:09:23 ON 01 AUG 2006  
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s muc1 and (Sm (w) 3)  
L1 22 MUC1 AND (SM (W) 3)


=> duplicate remove l1  
DUPLICATE PREFERENCE IS 'CAPLUS, BIOTECHNO, ESBIOBASE'  
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n  
PROCESSING COMPLETED FOR L1  
L2 11 DUPLICATE REMOVE L1 (11 DUPLICATES REMOVED)

=> d l2 bib abs 1-11

L2 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:41229 CAPLUS  
DN 140:105266  
TI Boroprolone compound combination therapy for various diseases  
IN Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry  
PA Point Therapeutics, Inc., USA  
SO PCT Int. Appl., 125 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004004661	A2	20040115	WO 2003-US21547	20030709
	WO 2004004661	A3	20051229		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2491474	AA	20040115	CA 2003-2491474	20030709
	AU 2003248921	A1	20040123	AU 2003-248921	20030709
	US 2004077601	A1	20040422	US 2003-616694	20030709
	US 2005084490	A1	20050421	US 2003-616409	20030709
	EP 1578362	A2	20050928	EP 2003-763433	20030709
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2006506442	T2	20060223	JP 2004-562639	20030709
	CN 1802090	A	20060712	CN 2003-821282	20030709
PRAI	US 2002-394856P	P	20020709		
	US 2002-414978P	P	20021001		
	US 2003-466435P	P	20030428		
	WO 2003-US21547	W	20030709		

GI



AB A method is provided for treating subjects with combination therapy including compds. of Formula I (wherein m is an integer between 0 and 10, inclusive; A and A1 may be L- or D-amino acid residues, the C bonded to B is in the L-configuration, and each X1 and X2 is, independently, a hydroxy group or a group capable of being hydrolyzed to a hydroxy group in aqueous solution at physiol. pH). It was surprisingly discovered that this combination enhanced the efficacy of both agents, and that administration of Formula I compds. induced cytokine and chemokine production in vivo. The combinations can be used to enhanced ADCC, stimulate immune responses and /or patient and treat certain disorders. The invention also relates to kits and compns. relating to such combinations.

L2 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:41226 CAPLUS

DN 140:105321

TI Methods and compositions relating to isoleucine boroproline compounds

IN Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry

PA Point Therapeutics, Inc., USA

SO PCT Int. Appl., 152 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004004658	A2	20040115	WO 2003-US21405	20030709
	WO 2004004658	A3	20050804		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2491466	AA	20040115	CA 2003-2491466	20030709
	AU 2003265264	A1	20040123	AU 2003-265264	20030709
	US 2004077601	A1	20040422	US 2003-616694	20030709
	US 2005084490	A1	20050421	US 2003-616409	20030709
	EP 1578434	A2	20050928	EP 2003-763380	20030709
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006507352	T2	20060302	JP 2004-562634	20030709
	CN 1802090	A	20060712	CN 2003-821282	20030709
PRAI	US 2002-394856P	P	20020709		
	US 2002-414978P	P	20021001		
	US 2003-466435P	P	20030428		
	WO 2003-US21405	W	20030709		

OS MARPAT 140:105321

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I,

AmNHCH(CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>)COAlR) (where Am and Al are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptioly-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl ( $\alpha$ -aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.

L2 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

AN 1999:568459 CAPLUS

DN 131:298415

TI Expression of core 2  $\beta$ -1,6-N-acetylglucosaminyltransferase in human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes

AU Beum, Paul V.; Singh, Jaswant; Burdick, Michael; Hollingsworth, Michael A.; Cheng, Pi-Wan

CS Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA

SO Journal of Biological Chemistry (1999), 274(35), 24641-24648  
CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB Many tumor-associated epitopes possess carbohydrate as a key component, and thus changes in the activity of glycosyltransferases could play a role in generating these epitopes. In this report the authors describe the stable transfection of a human pancreatic adenocarcinoma cell line, Panc1-MUC1, with the cDNA for mucin core 2 GlcNAc-transferase (C2GnT), which creates the core 2  $\beta$ -1,6 branch in mucin-type glycans. These cells lack endogenous C2GnT activity but express a recombinant human MUC1 cDNA. C2GnT-transfected clones expressing different levels of C2GnT were characterized using monoclonal antibodies CC49, CSLEX-1, and SM-3, which recognize tumor-associated epitopes. Increased C2GnT expression led to greatly diminished expression of the CC49 epitope, which the authors identified as NeuAc $\alpha$ 2,6-(Gal $\beta$ 1,3)GalNAc $\alpha$ -Ser/Thr in the Panc1-MUC1 cells. This was accompanied by the emergence of the CSLEX-1 epitope, sialyl Lewis x (NeuAc $\alpha$ 2,3Gal $\beta$ 1,4(Fuc $\alpha$ 1,3)-GlcNAc-R), an important selectin ligand. Despite this, however, the C2GnT transfectants could not bind to selectins. Increased C2GnT expression also led to masking of the SM-3 peptide epitope, which persisted after the removal of sialic acid, further suggesting greater complexity of the core 2-associated O-glycans on MUC1. The results of this study suggest that C2GnT could play a regulatory role in the expression of certain tumor-associated epitopes.

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:25098 CAPLUS

DN 130:221860

TI A short synthetic peptide (DTRPAP) induces anti-mucin (MUC-1) antibody, which is reactive with human ovarian and breast cancer cells

AU Avichezer, Dody; Taylor-Papadimitriou, Joyce; Arnon, Ruth

CS Department of Immunology, The Weizmann Institute of Science, Rehovot, 76100, Israel

SO Cancer Biochemistry Biophysics (1998), 16(1-2), 113-128  
CODEN: CABCD4; ISSN: 0305-7232

PB Gordon & Breach Science Publishers

DT Journal

LA English

AB The present study describes the production of a synthetic hexapeptide

(DTRPAP)-based anti-mucin (MUC-1) antibody, similar to those produced using either the intact mucin antigen or tumor exts. This antibody was generated by immunization of rabbits with the synthetic peptide conjugated to bovine serum albumin as a carrier. Using both the ELISA and FACS anal. methods, we have shown that the antibody is reactive with human ovarian and breast cancer cells, but not with normal epithelial breast cells. This antibody is different from the previously reported anti-mucin HMFG-1, HMFG-2 and SM-3 monoclonal antibodies, since competitive expts. with the free synthetic peptide revealed only a 30% inhibition of HMFG-1 binding to the ovarian (OVCAR-3) cancer cells, as compared to 78% inhibition of the anti-synthetic peptide antibody. The peptide was non-inhibitory for HMFG-2, and induced a significant and reproducible stimulation of the SM-3 binding activity to the tumor cells.

RE.CNT 19      THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2      ANSWER 5 OF 11    CAPLUS    COPYRIGHT 2006 ACS on STN DUPLICATE 2  
AN      1995:755226    CAPLUS  
DN      123:195339  
TI      Association of sialyl-Lewisa and sialyl-Lewisx with MUC-1 apomucin in a  
pancreatic cancer cell line  
AU      Ho, Jenny J. L.; Siddiki, Bader; Kim, Young S.  
CS      Gastrointestinal Research Lab., Univ. of California, San Francisco, CA,  
USA  
SO      Cancer Research (1995), 55(16), 3659-63  
CODEN: CNREA8; ISSN: 0008-5472  
PB      American Association for Cancer Research  
DT      Journal  
LA      English  
AB      The authors have shown previously that the mucins of the human pancreatic  
cancer cell line, SW1990, have both sialyl-Lewisa and sialyl-Lewisx  
carbohydrate ligands that are implicated in tumor cell metastasis. In the  
present study, the authors undertook to identify the protein core of these  
mucins. SW1990 mucins that carry sialyl-Lewisa and sialyl-Lewisx bound to  
the MUC1 peptide-specific mAb 139H2. Removal of most of the  
sialic acids from SW1990 mucins by neuraminidase greatly enhanced binding  
of two other MUC1 peptide specific antibodies, HMFG-2 and  
SM-3. After removal of sialic acids, most of the mucins  
rich in sialyl-Lewisa and sialyl-Lewisx oligosaccharides no longer bound  
to a DEAE-cellulose column at pH 8.0. These results indicate that at  
least part of the sialyl-Lewisa and sialyl-Lewisx in SW1990 cells is  
associated with the MUC1 polypeptide. Moreover, sialic acids play  
an important role in determining the net neg. charge of sialyl-Lewisa and  
sialyl-Lewisx rich mucins and in obscuring MUC1 peptide regions.

L2      ANSWER 6 OF 11    CAPLUS    COPYRIGHT 2006 ACS on STN DUPLICATE 3  
AN      1995:590744    CAPLUS  
DN      123:54046  
TI      Access to peptide regions of a surface mucin (MUC1) is reduced  
by sialic acids  
AU      Ho, Jenny J. L.; Cheng, Sandra; Kim, Y. S.  
CS      Gastrointestinal Research Lab., Veterans Affairs Medical Center,  
University of California, San Francisco, CA, USA  
SO      Biochemical and Biophysical Research Communications (1995), 210(3), 866-73  
CODEN: BBRCA9; ISSN: 0006-291X  
PB      Academic  
DT      Journal  
LA      English  
AB      Mucinous glycoproteins are present on the surfaces of tumor cells.  
Knowledge of which parts of the mucin mol. are accessible targets for  
cells of the immune system is important in the development of successful  
therapeutic approaches. One breast (ZR-75-1), two colon (Colo 205 and  
SW1116), and three pancreas (Capan-2, HPAF and SW1990) cancer cell lines

were examined. The reactivities of antibodies HMFG-2, specific for the tripeptide (DTR) in the 20 amino acid tandem repeat of MUC1, and SM-3 (PDTRP) were greatly enhanced by pre-treating cells with an inhibitor of O-glycosylation, benzyl- $\alpha$ -N-acetylgalactosamide. However, desialylation of cell surfaces with neuraminidase or pre-treatment with an inhibitor of carbohydrate processing, monensin, also greatly enhanced the reactivities of HMFG-2, SM-3 and HMFG-1 (PDTR). Thus, sialic acids on termini of neighboring oligosaccharides significantly limit access to the peptide region recognized by antibodies HMFG-1/2 and SM-3.

L2 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4

AN 1995:510392 CAPLUS

DN 122:309588

TI Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells  
AU Stadie, Tanja R. E.; Chai, Wengang; Lawson, Alexander M.; Byfield, Peter G.; Hanisch, Franz-Georg

CS Institute Immunobiology, Univ. Clinic, Cologne, Germany

SO European Journal of Biochemistry (1995), 229(1), 140-7

CODEN: EJBCAI; ISSN: 0014-2956

PB Springer

DT Journal

LA English

AB A synthetic peptide [TAP25, (T1aAPPAHGVT9S10APDT14RPAPGS20)T1bAPPA5b] corresponding to one repeat (T1a-S20) and five overlapping amino acids (T1b-A5b) of the MUC1 core protein served as an acceptor substrate for in vitro glycosylation. TAP25 was glycosylated using the detergent-solubilized UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases from the breast carcinoma cell line T47D, the colon carcinoma cell line HT29 and from human premature skim milk. The glycosylated peptides were isolated by ultrafiltration, purified by reverse-phase HPLC and further analyzed by liquid secondary ion mass spectrometry (LSIMS). Three different glycosylation species, mono-, di- and triglycosylated peptides were identified. Automated Edman sequencing and LSIMS of proteolytic fragments independently revealed the sites of GalNAc incorporation and confirmed that the threonine residues Thr9 and Thr1b are the preferred sites of glycosylation independent of the enzyme source, while Thr14 remained non-glycosylated even with the enzyme preparation from milk. In addition, evidence was obtained that at least 20% of the glycosylated peptides exhibited GalNAc incorporation at Ser20. On the basis of kinetic studies a preferred sequence of GalNAc addition to the three acceptor sites has been concluded (Thr9  $\rightarrow$  Thr1b  $\rightarrow$  Ser20). Although Thr14 within the PDTRP motif of the tandem repeats remained nonglycosylated, the introduction of GalNAc into adjacent positions significantly decreased the immunoreactivity of antibodies SM-3, HMFG-1 and HMFG-2 defining overlapping epitopes of this motif. It is assumed that glycosylation at Thr9, Thr1b and Ser20 distorts the peptide conformation of the binding epitope.

L2 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 5

AN 1993:166346 CAPLUS

DN 118:166346

TI Multiple forms of intracellular and secreted mucins in a pancreatic cancer cell line

AU Ho, Jenny J. L.; Bi, Ning; Siddiki, Bader; Chung, Yong Suk; Yuan, Mei; Kim, Young S.

CS Gastrointest. Res. Lab., Veterans Aff. Med. Cent., San Francisco, CA, 94121, USA

SO Cancer Research (1993), 53(4), 884-90

CODEN: CNREA8; ISSN: 0008-5472

DT Journal

LA English

AB Mucins have been implicated in circumventing the defenses of the body against tumorigenesis. A better understanding of the structures of mucins may assist in the development of new therapeutic approaches. Monoclonal antibody Ea6, developed against mucins purified from xenografts of the pancreatic cancer cell line SW1990, was used to identify a new type of pancreatic cancer mucin. The following characteristics suggest that Ea6 antibody reacts with the core structure of O-linked oligosaccharides, the Tn antigen (N-acetylgalactosamine-serine/threonine): (a) increased reactivity with ovine and bovine submaxillary mucins after desialylation; (b) reactivity was inhibitable by N-acetylgalactosamine; and (c) no reactivity with blood group A oligosaccharides. Ea6 mucins from cultured SW1990 cells had lower buoyant densities (1.36 vs. 1.44 g/mL) than mucins identified by another monoclonal antibody directed against SW1990 mucins, SPan-1, and were less acidic. High d. and mol. mass ( $\geq 400$  kDa) secreted antigens were not affected by sulfhydryl bond reduction. After partial deglycosylation secreted SPan-1 antigens reacted with MUC1 peptide specific antibodies, SM-3 and HMFG-2, as well as polyclonal antisera directed against deglycosylated xenograft mucins. However, Ea6 antigens did not. SW1990 cytosol also contained SPan-1 antigens with apparent mol. wts. of 160,000 and 210,000 and low buoyant densities ( $\leq 1.22$  g/mL). These reacted with monoclonal antibodies specific for the MUC1 apomucin with no prior treatment. No Ea6 reactivity was detected with this fraction. Thus, Ea6 antibody identifies a new population of mucins that is distinct from SPan-1 mucins.

L2 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 6

AN 1992:212528 CAPLUS

DN 116:212528

TI Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice

AU Peat, Nigel; Gendler, Sandra J.; Lalani, El Nasir; Duhig, Trevor; Taylor-Papadimitriou, Joyce

CS Imp. Cancer Res. Fund, London, WC2A 3PX, UK

SO Cancer Research (1992), 52(7), 1954-60

CODEN: CNREA8; ISSN: 0008-5472

DT Journal

LA English

AB The human MUC1 gene codes for the core protein of a mucin which is expressed by glandular epithelia and the carcinomas which develop from these tissues. The core protein is aberrantly glycosylated in cancers, and some antibodies show specificity in their reactions with the cancer-associated mucin, which also contains epitopes recognized by T-cells from breast and pancreatic cancer patients. For evaluating the potential use of mucin-reactive antibodies and mucin-based immunogens in cancer patients, a mouse model, expressing the MUC1 gene product PEM (polymorphic epithelial mucin) as a self antigen, would be extremely useful. To this end, the authors have developed transgenic mouse strains expressing the human MUC1 gene product in a tissue-specific manner. The TG4 mouse strain was established using a 40-kilobase fragment containing 4.5 kilobases of 5' and 27 kilobases of 3' flanking sequence. The TG18 strain was developed using a 10.6-kilobase SacII fragment from the 40-kilobase fragment; this fragment contained 1.6 kilobases of 5' sequence and 1.9 kilobases of 3' flanking sequence. Both strains showed tissue specificity of expression of the MUC1 gene, which was very similar to the profile of expression seen in human tissues. The antibody SM-3 is directed to a core protein epitope, which is selectively exposed in breast cancers and which shows a more restricted distribution on normal human tissues. It was established that the distribution of the SM-3 epitope of PEM in the tissues of the transgenic mice is similar to that seen in humans. The transgenic mouse strains described here should form the basis for the development of a preclin. model for the evaluation of PEM-based antigens and of antibodies directed to PEM in cancer therapy.



L2 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 7

AN 1991:605464 CAPLUS

DN 115:205464

TI Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins

AU Baeckstroem, Dan; Hansson, Gunnar C.; Nilsson, Olle; Johansson, Christina; Gendler, Sandra J.; Lindholm, Leif

CS Dep. Med. Biochem., Univ. Goeteborg, Goeteborg, S-400 33, Swed.

SO Journal of Biological Chemistry (1991), 266(32), 21537-47  
CODEN: JBCHA3; ISSN: 0021-9258

DT Journal

LA English

AB Two mucin-type glycoproteins detected by the monoclonal antibody C50, which reacts with the carcinoma-associated sialyl-Lewis a and sialyl-lactotetraoase epitopes, were found in secreted and solubilized materials from the colon carcinoma cell line COLO 205. The larger glycoprotein (H-CanAg; heavy cancer antigen) was predominantly found in exts. of cells grown in vitro or as nude mice xenografts, whereas the smaller species (L-CanAg; light cancer antigen) was the major component in spent culture medium and serum from grafted mice. H-CanAg is apparently membrane bound. The 2 glycoproteins were purified from xenograft exts. and spent culture medium using perchloric acid precipitation, monoclonal antibody affinity purification, ion exchange chromatog., and gel filtration. Neither glycoprotein was affected by reduction and alkylation in guanidine HCl. Using SDS-PAGE, relative mol. masses were estimated to be 600-800 kDa for H-CanAg and 150-300 kDa for L-CanAg. Carbohydrate anal. revealed that the CanAg glycoproteins were highly glycosylated (81-89% carbohydrate by weight), carrying carbohydrate chains with average lengths of 13-18 sugars which were rich in fucose and sialic acid (2-3 residues/chain for each sugar). L-CanAg isolated from spent medium was glycosylated to a higher degree than its counterpart from xenograft extract. Immunochem. studies of the intact glycoproteins showed that both H-CanAg and L-CanAg expressed the monoclonal antibody-defined, sialic acid-containing carbohydrate epitopes CA203 and CA242 as well as the Lewis a blood group antigen, whereas only H-CanAg appeared to carry the sialyl-Lewis x epitope. A rabbit antiserum against the cytoplasmic C-terminal part of the MUC1 gene product, core protein of the carcinoma-associated polymorphic epithelial mucin (PEM) and DU-PAN-2, reacted with H-CanAg. Deglycosylated H-CanAg but not L-CanAg was recognized by the monoclonal antibodies SM-3 and HMFG-2, directed to the tandem repeat of the PEM apoprotein. Comparison of amino acid comps. confirmed that H-CanAg apoprotein is closely related to the MUC1 protein whereas L-CanAg is not. Thus, colon carcinoma cells can express 2 mucins with several carcinoma-associated carbohydrate epitopes in common but differing in core protein structure and cellular localization.

L2 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 8

AN 1991:605798 CAPLUS

DN 115:205798

TI Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity

AU Lalani, El Nasir; Berdichevsky, Feodor; Boshell, Martina; Shearer, Moira; Wilson, David; Stauss, Hans; Gendler, Sandra J.; Taylor-Papadimitriou, Joyce

CS Imp. Cancer Res. Fund, London, WC2A 3PX, UK

SO Journal of Biological Chemistry (1991), 266(23), 15420-6  
CODEN: JBCHA3; ISSN: 0021-9258

DT Journal

LA English

AB The human epithelial mucin which is the product of the MUC1 gene is expressed by many carcinomas, including those of breast, ovary, colon, and lung. The core protein is aberrantly glycosylated in the tumors

resulting in the exposure or appearance of novel epitopes. To examine the possibility of using the MUC1 gene and its products in active immunization against breast and other carcinomas, the authors have developed a syngeneic mouse model, by transfecting the gene into the mouse mammary epithelial tumor cell 410.4. An 8.3-kilobase EcoRI fragment of the gene was transfected using the expression vector pEMSV scribe  $\alpha 2$ . Transcripts of the correct size, initiating from the transcriptional start site seen in human cells, were observed in the transfectants. The mucin was expressed in the cytoplasm and in the membrane, and the glycosylation pattern appeared to be similar to that seen in human tumor cells, since the core protein epitopes recognized by antibodies HMFG-1, HMFG-2, and SM-3 were exposed. The 410.4 transfectants expressing the human mucin showed a reduction in tumor incidence at low inocula and a delay in tumor growth at higher inocula. Pretreatment with 104 transfectant cells could inhibit the development of tumors from a subsequent inoculum of 106 transfectants, but had no effect on the tumor development of the untransfected 410.4 cells. These results suggest that the human mucin expressed by the 410.4 cells may mobilize an immune response which inhibits tumor development. They also indicate that the mouse model will be useful for evaluation of efficacy of immunogens based on the MUC1 gene and its product.



A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI  
[Sign In] [Register]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search **PubMed** for **"epithelial mucin" and Sm-3** **Preview** **Go** **Clear**

☒ Limits ☐ Preview/Index **History** ☐ Clipboard ☐ Details

#### Limits: Publication Date to 1990

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Search	Most Recent Queries	Time	Result
<a href="#">#12</a>	Search "epithelial mucin" and Sm-3 Limits: Publication Date to 1990	13:28:20	<a href="#">4</a>
<a href="#">#10</a>	Search "epithelial mucin" and clone Limits: Publication Date to 1990	13:26:25	<a href="#">2</a>
<a href="#">#8</a>	Search "epithelial mucin" and cloning Limits: Publication Date to 1990	13:25:29	<a href="#">3</a>
<a href="#">#7</a>	Search "epithelial mucin" Limits: Publication Date to 1990	13:25:07	<a href="#">56</a>
<a href="#">#3</a>	Search "polymorphic epithelial mucin" Limits: Publication Date to 1990	13:20:34	<a href="#">14</a>
<a href="#">#2</a>	Search "polymorphic epithelial mucin"	13:20:16	<a href="#">101</a>
<a href="#">#1</a>	Search polymorphic epithelial mucin	13:20:08	<a href="#">2881</a>

[Clear History](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 25 2006 06:31:58